WO2013066834A1 - Compounds and methods - Google Patents
Compounds and methods Download PDFInfo
- Publication number
- WO2013066834A1 WO2013066834A1 PCT/US2012/062509 US2012062509W WO2013066834A1 WO 2013066834 A1 WO2013066834 A1 WO 2013066834A1 US 2012062509 W US2012062509 W US 2012062509W WO 2013066834 A1 WO2013066834 A1 WO 2013066834A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- phenyl
- aryl
- heteroaryl
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 144
- 238000000034 method Methods 0.000 title claims abstract description 35
- -1 hydroxy, cyano, amino Chemical group 0.000 claims description 206
- 125000000217 alkyl group Chemical group 0.000 claims description 138
- 150000003839 salts Chemical class 0.000 claims description 88
- 125000001072 heteroaryl group Chemical group 0.000 claims description 76
- 125000003118 aryl group Chemical group 0.000 claims description 67
- 125000005843 halogen group Chemical group 0.000 claims description 41
- 102000003964 Histone deacetylase Human genes 0.000 claims description 40
- 108090000353 Histone deacetylase Proteins 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 13
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 11
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000005493 quinolyl group Chemical group 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 31
- 238000011282 treatment Methods 0.000 description 24
- 101710177326 Histone deacetylase 9 Proteins 0.000 description 23
- 239000000203 mixture Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 11
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 11
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 11
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 11
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 101001032113 Homo sapiens Histone deacetylase 7 Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 7
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 206010052779 Transplant rejections Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 6
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 201000004085 CLL/SLL Diseases 0.000 description 4
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical group C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010025327 Lymphopenia Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 231100001023 lymphopenia Toxicity 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000008184 oral solid dosage form Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 2
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 2
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 2
- DZQVRXWFPZNPPQ-UHFFFAOYSA-N 3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound FC(F)(F)C=1N=CON=1 DZQVRXWFPZNPPQ-UHFFFAOYSA-N 0.000 description 2
- VSHDLCAJLJJEFH-IZZDOVSWSA-N 3-[(E)-2-[1-(4-phenylphenyl)sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound n1oc(C(F)(F)F)nc1\C=C\c1ccn(S(=O)(=O)c2ccc(cc2)-c2ccccc2)c1 VSHDLCAJLJJEFH-IZZDOVSWSA-N 0.000 description 2
- JRMKVZKMDUHYQR-QPJJXVBHSA-N 3-[(e)-2-[1-(4-methylphenyl)sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C=C(\C=C\C=2N=C(ON=2)C(F)(F)F)C=C1 JRMKVZKMDUHYQR-QPJJXVBHSA-N 0.000 description 2
- XLJTYOXHVXIPNI-GQCTYLIASA-N 3-[(e)-2-[1-(5-pyridin-2-ylthiophen-2-yl)sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2SC(=CC=2)C=2N=CC=CC=2)=N1 XLJTYOXHVXIPNI-GQCTYLIASA-N 0.000 description 2
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000007368 Ataxin-7 Human genes 0.000 description 2
- 108010032953 Ataxin-7 Proteins 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- 102100036465 Autoimmune regulator Human genes 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039869 Histone H2B type F-S Human genes 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 2
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 2
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 201000003278 cryoglobulinemia Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000003838 furazanyl group Chemical group 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- DKPFFYHWCHMGBD-FPYGCLRLSA-N n,n-dimethyl-4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylaniline Chemical compound C1=CC(N(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C=2N=C(ON=2)C(F)(F)F)C=C1 DKPFFYHWCHMGBD-FPYGCLRLSA-N 0.000 description 2
- LMBUQQMZPLLXKJ-CMDGGOBGSA-N n-(2-fluorophenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound FC1=CC=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 LMBUQQMZPLLXKJ-CMDGGOBGSA-N 0.000 description 2
- GFEMSCRGJMTSCR-MDZDMXLPSA-N n-(2-phenylethyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCCC=2C=CC=CC=2)=N1 GFEMSCRGJMTSCR-MDZDMXLPSA-N 0.000 description 2
- WRNJITHGYZQKLX-RMKNXTFCSA-N n-(3,4-dimethoxyphenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 WRNJITHGYZQKLX-RMKNXTFCSA-N 0.000 description 2
- VRWQFAYMRKUEDI-BQYQJAHWSA-N n-(3-fluorophenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C=C(\C=C\C=3N=C(ON=3)C(F)(F)F)C=CC=2)=C1 VRWQFAYMRKUEDI-BQYQJAHWSA-N 0.000 description 2
- KUGIPDHZEHKPBY-JXMROGBWSA-N n-(4-methylphenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 KUGIPDHZEHKPBY-JXMROGBWSA-N 0.000 description 2
- JMUSCPUFDZJOHH-IZZDOVSWSA-N n-[2-(1h-indol-2-yl)ethyl]-n-methyl-4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylaniline Chemical compound C=1C2=CC=CC=C2NC=1CCN(C)C(C=C1)=CC=C1S(=O)(=O)N(C=1)C=CC=1\C=C\C1=NOC(C(F)(F)F)=N1 JMUSCPUFDZJOHH-IZZDOVSWSA-N 0.000 description 2
- YSOUARJPJHBHNK-VMPITWQZSA-N n-[2-methoxy-5-(trifluoromethyl)phenyl]-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound COC1=CC=C(C(F)(F)F)C=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 YSOUARJPJHBHNK-VMPITWQZSA-N 0.000 description 2
- NNYJBQGLTQDPRE-DHZHZOJOSA-N n-[4-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]phenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=2)=N1 NNYJBQGLTQDPRE-DHZHZOJOSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 125000005968 oxazolinyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000006845 reticulosarcoma Diseases 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 230000022379 skeletal muscle tissue development Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- OTEVMULOEURSKR-HULFFUFUSA-N (e)-2-phenyl-n-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]phenyl]ethenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(NS(=O)(=O)\C=C\C=3C=CC=CC=3)C=CC=2)=N1 OTEVMULOEURSKR-HULFFUFUSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HUSZLGZRDMBKGJ-DHZHZOJOSA-N 1-phenyl-n-[4-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]phenyl]methanesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=CC(NS(=O)(=O)CC=3C=CC=CC=3)=CC=2)=N1 HUSZLGZRDMBKGJ-DHZHZOJOSA-N 0.000 description 1
- QPFHLZBEMVUXRK-DHZHZOJOSA-N 1-phenyl-n-[[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methyl]methanamine Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(CNCC=3C=CC=CC=3)=CC=2)=N1 QPFHLZBEMVUXRK-DHZHZOJOSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- MKTVUKPYYZJCJT-JXMROGBWSA-N 2-[2-(1h-indol-2-yl)ethyl-[[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methyl]amino]ethanol Chemical compound C=1C2=CC=CC=C2NC=1CCN(CCO)CC(C=C1)=CC=C1S(=O)(=O)N(C=1)C=CC=1\C=C\C1=NOC(C(F)(F)F)=N1 MKTVUKPYYZJCJT-JXMROGBWSA-N 0.000 description 1
- SENFZSMVDURVLG-VMPITWQZSA-N 2-methyl-n-[[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methyl]propan-1-amine Chemical compound C1=CC(CNCC(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C=2N=C(ON=2)C(F)(F)F)C=C1 SENFZSMVDURVLG-VMPITWQZSA-N 0.000 description 1
- NFYPYNZXEYOLIR-RMKNXTFCSA-N 3,4-dimethoxy-n-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]phenyl]benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)NC1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 NFYPYNZXEYOLIR-RMKNXTFCSA-N 0.000 description 1
- DHDCPWHDRGMWGD-BJMVGYQFSA-N 3,4-dimethoxy-n-[4-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]phenyl]benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)NC(C=C1)=CC=C1\C=C\C1=NOC(C(F)(F)F)=N1 DHDCPWHDRGMWGD-BJMVGYQFSA-N 0.000 description 1
- AUSAUGSRMZLWAS-MDZDMXLPSA-N 3-[(E)-2-[1-(3-phenylphenyl)sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound n1oc(C(F)(F)F)nc1\C=C\c1ccn(S(=O)(=O)c2cccc(c2)-c2ccccc2)c1 AUSAUGSRMZLWAS-MDZDMXLPSA-N 0.000 description 1
- NJTVIHSXAMOAAV-VOTSOKGWSA-N 3-[(e)-2-[1-(3-pyridin-3-ylphenyl)sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=C(C=CC=2)C=2C=NC=CC=2)=N1 NJTVIHSXAMOAAV-VOTSOKGWSA-N 0.000 description 1
- ZKXDZBYIMHXXSU-SNAWJCMRSA-N 3-[(e)-2-[1-(3-pyridin-4-ylphenyl)sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=C(C=CC=2)C=2C=CN=CC=2)=N1 ZKXDZBYIMHXXSU-SNAWJCMRSA-N 0.000 description 1
- FOQSFHIOIAGIQG-FPYGCLRLSA-N 3-[(e)-2-[1-(4-pyridin-3-ylphenyl)sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(=CC=2)C=2C=NC=CC=2)=N1 FOQSFHIOIAGIQG-FPYGCLRLSA-N 0.000 description 1
- NPBXCHWICFDMMJ-LZCJLJQNSA-N 3-[(e)-2-[1-(4-pyridin-4-ylphenyl)sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(=CC=2)C=2C=CN=CC=2)=N1 NPBXCHWICFDMMJ-LZCJLJQNSA-N 0.000 description 1
- ZPINWYGWMUHUSY-SNAWJCMRSA-N 3-[(e)-2-[1-[3-(1h-pyrazol-4-yl)phenyl]sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=C(C=CC=2)C2=CNN=C2)=N1 ZPINWYGWMUHUSY-SNAWJCMRSA-N 0.000 description 1
- KSKRKLNLLQOFAT-LZCJLJQNSA-N 3-[(e)-2-[1-[4-(1h-pyrazol-4-yl)phenyl]sulfonylpyrrol-3-yl]ethenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(=CC=2)C2=CNN=C2)=N1 KSKRKLNLLQOFAT-LZCJLJQNSA-N 0.000 description 1
- UQGRZIKVVUWAGN-BQYQJAHWSA-N 3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]-n-[(3,4,5-trimethoxyphenyl)methyl]benzenesulfonamide Chemical compound COC1=C(OC)C(OC)=CC(CNS(=O)(=O)C=2C=C(\C=C\C=3N=C(ON=3)C(F)(F)F)C=CC=2)=C1 UQGRZIKVVUWAGN-BQYQJAHWSA-N 0.000 description 1
- FERIWGLCCLLDNV-RUDMXATFSA-N 3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]-n-[4-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC=2C=CC(=CC=2)C(F)(F)F)=N1 FERIWGLCCLLDNV-RUDMXATFSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N 3-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(Br)=C1 PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JNDJOHCFGLNION-ZZXKWVIFSA-N 4-[[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methyl]morpholine Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(CN3CCOCC3)=CC=2)=N1 JNDJOHCFGLNION-ZZXKWVIFSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-M 4-aminobenzoate Chemical compound NC1=CC=C(C([O-])=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-M 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- VVGXRMXGACSXCB-JXMROGBWSA-N 4-methyl-n-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]phenyl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 VVGXRMXGACSXCB-JXMROGBWSA-N 0.000 description 1
- YXCJYRIJGWAHGM-NTEUORMPSA-N 4-phenyl-N-[3-[(E)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]phenyl]benzenesulfonamide Chemical compound n1oc(C(F)(F)F)nc1\C=C\c1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccccc2)c1 YXCJYRIJGWAHGM-NTEUORMPSA-N 0.000 description 1
- SEHMKTXAKVVIIR-OVCLIPMQSA-N 4-phenyl-N-[4-[(E)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]phenyl]benzenesulfonamide Chemical compound n1oc(C(F)(F)F)nc1\C=C\c1ccc(NS(=O)(=O)c2ccc(cc2)-c2ccccc2)cc1 SEHMKTXAKVVIIR-OVCLIPMQSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000007372 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 0 C=**1C=CC(NS(c2cccc(C=Cc3n[o]c(C(F)(F)F)n3)c2)(=O)=O)=CC=C1 Chemical compound C=**1C=CC(NS(c2cccc(C=Cc3n[o]c(C(F)(F)F)n3)c2)(=O)=O)=CC=C1 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- 101001035694 Homo sapiens Polyamine deacetylase HDAC10 Proteins 0.000 description 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000308605 Irvingia smithii Species 0.000 description 1
- 235000002222 Irvingia smithii Nutrition 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000055120 MEF2 Transcription Factors Human genes 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- FAGDCEJJFBHKHO-BUHFOSPRSA-N N-(2-phenylphenyl)-3-[(E)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound n1oc(C(F)(F)F)nc1\C=C\c1cccc(S(=O)(=O)Nc2ccccc2-c2ccccc2)c1 FAGDCEJJFBHKHO-BUHFOSPRSA-N 0.000 description 1
- AOCNFIMIWFBINM-KXWKATCLSA-N N-(3-phenylprop-2-enyl)-3-[(E)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound n1oc(C(F)(F)F)nc1\C=C\c1cccc(S(=O)(=O)NCC=Cc2ccccc2)c1 AOCNFIMIWFBINM-KXWKATCLSA-N 0.000 description 1
- JYVFPZHAQWIDLL-NTEUORMPSA-N N-(4-phenylphenyl)-3-[(E)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound n1oc(C(F)(F)F)nc1\C=C\c1cccc(S(=O)(=O)Nc2ccc(cc2)-c2ccccc2)c1 JYVFPZHAQWIDLL-NTEUORMPSA-N 0.000 description 1
- UELXSIWRJLBZOW-OVCLIPMQSA-N N-(4-phenylphenyl)-4-[(E)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound n1oc(C(F)(F)F)nc1\C=C\c1ccc(S(=O)(=O)Nc2ccc(cc2)-c2ccccc2)cc1 UELXSIWRJLBZOW-OVCLIPMQSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 description 1
- 208000025237 Polyendocrinopathy Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WOSJJUCAIZDXAT-ZZXKWVIFSA-N [4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methanamine Chemical compound C1=CC(CN)=CC=C1S(=O)(=O)N1C=C(\C=C\C=2N=C(ON=2)C(F)(F)F)C=C1 WOSJJUCAIZDXAT-ZZXKWVIFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001723 carbon free-radicals Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000020470 microtubule-based transport Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- UYSWORDFQHLEBF-CCEZHUSRSA-N n,n-dibenzyl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)N(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=N1 UYSWORDFQHLEBF-CCEZHUSRSA-N 0.000 description 1
- GTQKUOBHOHKZMI-VMPITWQZSA-N n,n-dimethyl-1-[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methanamine Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C=2N=C(ON=2)C(F)(F)F)C=C1 GTQKUOBHOHKZMI-VMPITWQZSA-N 0.000 description 1
- YCSRZRFMPKJPRF-CCEZHUSRSA-N n,n-diphenyl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 YCSRZRFMPKJPRF-CCEZHUSRSA-N 0.000 description 1
- QVRFWQPIBWNSHN-CCEZHUSRSA-N n-(1,2-diphenylethyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC(CC=2C=CC=CC=2)C=2C=CC=CC=2)=N1 QVRFWQPIBWNSHN-CCEZHUSRSA-N 0.000 description 1
- POAPLXBDGJEVLD-FNORWQNLSA-N n-(1,3-benzodioxol-5-ylmethyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCC=2C=C3OCOC3=CC=2)=N1 POAPLXBDGJEVLD-FNORWQNLSA-N 0.000 description 1
- DCXZXBVERRBPHX-JXMROGBWSA-N n-(1h-indol-3-ylmethyl)-1-[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methanamine Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(CNCC=3C4=CC=CC=C4NC=3)=CC=2)=N1 DCXZXBVERRBPHX-JXMROGBWSA-N 0.000 description 1
- IQPDTPUCIWGLMH-XBXARRHUSA-N n-(1h-indol-5-ylmethyl)-1-[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methanamine Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(CNCC=3C=C4C=CNC4=CC=3)=CC=2)=N1 IQPDTPUCIWGLMH-XBXARRHUSA-N 0.000 description 1
- KXQUFVRUGPKEQS-CMDGGOBGSA-N n-(2,3-dihydro-1h-inden-2-yl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC2CC3=CC=CC=C3C2)=N1 KXQUFVRUGPKEQS-CMDGGOBGSA-N 0.000 description 1
- XPUWLXSQKNAEEB-QPJJXVBHSA-N n-(2,4-difluorophenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound FC1=CC(F)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 XPUWLXSQKNAEEB-QPJJXVBHSA-N 0.000 description 1
- NEAJUVGDIWYDNW-MDZDMXLPSA-N n-(2-methoxyphenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound COC1=CC=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 NEAJUVGDIWYDNW-MDZDMXLPSA-N 0.000 description 1
- VKQHQUUJOYUCNA-VAWYXSNFSA-N n-(2-methylpropyl)-n-phenyl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C=1C=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=CC=1S(=O)(=O)N(CC(C)C)C1=CC=CC=C1 VKQHQUUJOYUCNA-VAWYXSNFSA-N 0.000 description 1
- JJDJEFIZWLTBNO-BQYQJAHWSA-N n-(2-pyridin-2-ylethyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCCC=2N=CC=CC=2)=N1 JJDJEFIZWLTBNO-BQYQJAHWSA-N 0.000 description 1
- QTWXSKUTOBBKKV-BQYQJAHWSA-N n-(3-bromophenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC=2C=C(Br)C=CC=2)=N1 QTWXSKUTOBBKKV-BQYQJAHWSA-N 0.000 description 1
- KAENOUGVNWJORE-CMDGGOBGSA-N n-(3-methoxyphenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound COC1=CC=CC(NS(=O)(=O)C=2C=C(\C=C\C=3N=C(ON=3)C(F)(F)F)C=CC=2)=C1 KAENOUGVNWJORE-CMDGGOBGSA-N 0.000 description 1
- KXRDBHHJMXKOPV-RUDMXATFSA-N n-(4-bromophenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC=2C=CC(Br)=CC=2)=N1 KXRDBHHJMXKOPV-RUDMXATFSA-N 0.000 description 1
- UOSJRUGPYYENAF-RUDMXATFSA-N n-(4-chlorophenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC=2C=CC(Cl)=CC=2)=N1 UOSJRUGPYYENAF-RUDMXATFSA-N 0.000 description 1
- ITNVDCSTHJEGJV-XCVCLJGOSA-N n-(4-chlorophenyl)-4-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)NC=2C=CC(Cl)=CC=2)=N1 ITNVDCSTHJEGJV-XCVCLJGOSA-N 0.000 description 1
- PMEMFUVUHKSWAC-RMKNXTFCSA-N n-(4-cyanophenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC=2C=CC(=CC=2)C#N)=N1 PMEMFUVUHKSWAC-RMKNXTFCSA-N 0.000 description 1
- AIBCROSOJBROAV-RUDMXATFSA-N n-(4-hydroxyphenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=CC(O)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 AIBCROSOJBROAV-RUDMXATFSA-N 0.000 description 1
- JDXFPSPCMUNIFG-BJMVGYQFSA-N n-(4-methoxyphenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 JDXFPSPCMUNIFG-BJMVGYQFSA-N 0.000 description 1
- JGHAQHKTNKZKNZ-RUDMXATFSA-N n-(4-sulfamoylphenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 JGHAQHKTNKZKNZ-RUDMXATFSA-N 0.000 description 1
- QLFYOISCRKJNMR-KPKJPENVSA-N n-(4-tert-butylphenyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 QLFYOISCRKJNMR-KPKJPENVSA-N 0.000 description 1
- BMZOISGSRROMRE-JLHYYAGUSA-N n-(9-ethylcarbazol-3-yl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NS(=O)(=O)C(C=1)=CC=CC=1\C=C\C1=NOC(C(F)(F)F)=N1 BMZOISGSRROMRE-JLHYYAGUSA-N 0.000 description 1
- QFOXBRWEEXDQFE-VOTSOKGWSA-N n-(furan-2-ylmethyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCC=2OC=CC=2)=N1 QFOXBRWEEXDQFE-VOTSOKGWSA-N 0.000 description 1
- JZNAWOLKNYLPKH-VAWYXSNFSA-N n-(naphthalen-1-ylmethyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCC=2C3=CC=CC=C3C=CC=2)=N1 JZNAWOLKNYLPKH-VAWYXSNFSA-N 0.000 description 1
- JVOFLRNFDISKQU-VMPITWQZSA-N n-(pyridin-3-ylmethyl)-1-[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methanamine Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(CNCC=3C=NC=CC=3)=CC=2)=N1 JVOFLRNFDISKQU-VMPITWQZSA-N 0.000 description 1
- IUPCRSSGUSGVQI-VOTSOKGWSA-N n-(pyridin-3-ylmethyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCC=2C=NC=CC=2)=N1 IUPCRSSGUSGVQI-VOTSOKGWSA-N 0.000 description 1
- SCRVTFIQIIRYSY-ZZXKWVIFSA-N n-(pyridin-4-ylmethyl)-1-[4-[3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]pyrrol-1-yl]sulfonylphenyl]methanamine Chemical compound O1C(C(F)(F)F)=NC(\C=C\C2=CN(C=C2)S(=O)(=O)C=2C=CC(CNCC=3C=CN=CC=3)=CC=2)=N1 SCRVTFIQIIRYSY-ZZXKWVIFSA-N 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- SFLLXGJJXPFTCB-CMDGGOBGSA-N n-[2-(1h-benzimidazol-2-yl)ethyl]-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCCC=2NC3=CC=CC=C3N=2)=N1 SFLLXGJJXPFTCB-CMDGGOBGSA-N 0.000 description 1
- NBPRMCPZVVTAKG-SNAWJCMRSA-N n-[2-(1h-imidazol-5-yl)ethyl]-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCCC=2NC=NC=2)=N1 NBPRMCPZVVTAKG-SNAWJCMRSA-N 0.000 description 1
- XVNUFRVCERBRRA-CMDGGOBGSA-N n-[2-(1h-indol-3-yl)ethyl]-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCCC=2C3=CC=CC=C3NC=2)=N1 XVNUFRVCERBRRA-CMDGGOBGSA-N 0.000 description 1
- XCTMYGRPLJQJOG-VQHVLOKHSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 XCTMYGRPLJQJOG-VQHVLOKHSA-N 0.000 description 1
- KAAIGRSATHKGKK-RUDMXATFSA-N n-[4-(difluoromethoxy)phenyl]-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=CC(OC(F)F)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 KAAIGRSATHKGKK-RUDMXATFSA-N 0.000 description 1
- AZQKYPFHGQWDNB-RUDMXATFSA-N n-[4-(trifluoromethoxy)phenyl]-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NS(=O)(=O)C1=CC=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=C1 AZQKYPFHGQWDNB-RUDMXATFSA-N 0.000 description 1
- IUIVHBWEWOTUOE-CCEZHUSRSA-N n-benzhydryl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 IUIVHBWEWOTUOE-CCEZHUSRSA-N 0.000 description 1
- GOLJGUVFGWJNOG-MDZDMXLPSA-N n-benzyl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CC=CC=2)=N1 GOLJGUVFGWJNOG-MDZDMXLPSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZRQIKUNZSCNIHH-BUHFOSPRSA-N n-butyl-n-(2-phenylpropyl)-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C=1C=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=CC=1S(=O)(=O)N(CCCC)CC(C)C1=CC=CC=C1 ZRQIKUNZSCNIHH-BUHFOSPRSA-N 0.000 description 1
- CWLHGLJKYZXSNR-OUKQBFOZSA-N n-butyl-n-phenyl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C=1C=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=CC=1S(=O)(=O)N(CCCC)C1=CC=CC=C1 CWLHGLJKYZXSNR-OUKQBFOZSA-N 0.000 description 1
- JBIWMTHJWQYPGI-ZHACJKMWSA-N n-methyl-n-phenyl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound C=1C=CC(\C=C\C=2N=C(ON=2)C(F)(F)F)=CC=1S(=O)(=O)N(C)C1=CC=CC=C1 JBIWMTHJWQYPGI-ZHACJKMWSA-N 0.000 description 1
- MECXWHJAOCJEMO-VAWYXSNFSA-N n-naphthalen-1-yl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC=2C3=CC=CC=C3C=CC=2)=N1 MECXWHJAOCJEMO-VAWYXSNFSA-N 0.000 description 1
- MUBDRFWQYXCYRW-DHZHZOJOSA-N n-naphthalen-2-yl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC=2C=C3C=CC=CC3=CC=2)=N1 MUBDRFWQYXCYRW-DHZHZOJOSA-N 0.000 description 1
- FITDNPAMIIMJBR-KPKJPENVSA-N n-naphthalen-2-yl-4-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)NC=2C=C3C=CC=CC3=CC=2)=N1 FITDNPAMIIMJBR-KPKJPENVSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QSBVFJXTEHBKLD-DHZHZOJOSA-N n-phenyl-4-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=CC(=CC=2)S(=O)(=O)NC=2C=CC=CC=2)=N1 QSBVFJXTEHBKLD-DHZHZOJOSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GLDVNXGOZUSIIM-CMDGGOBGSA-N n-quinolin-4-yl-3-[(e)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethenyl]benzenesulfonamide Chemical compound O1C(C(F)(F)F)=NC(\C=C\C=2C=C(C=CC=2)S(=O)(=O)NC=2C3=CC=CC=C3N=CC=2)=N1 GLDVNXGOZUSIIM-CMDGGOBGSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000021629 neuronal intranuclear inclusion disease Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- UZGLIIJVICEWHF-UHFFFAOYSA-N octogen Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 UZGLIIJVICEWHF-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000009612 pediatric lymphoma Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- QPMDWIOUHQWKHV-ODZAUARKSA-M potassium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound [K+].OC(=O)\C=C/C([O-])=O QPMDWIOUHQWKHV-ODZAUARKSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 208000032620 x-linked multiple congenital anomalies-neurodevelopmental syndrome Diseases 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Definitions
- the present invention relates to compounds that inhibit histone deacetylase
- HDAC HDAC enzymes
- preparation of these compounds the preparation of these compounds, the use of these compounds in the treatment of diseases or conditions ameliorated by inhibition of HDAC activity and pharmaceutical compositions comprising these compounds.
- Chromatin organization involves DNA wound around histone octamers that form nucleosomes.
- Core histones with N-terminal tails extending from compact nucleosomal core particles can be acetylated or deacetylated at epsilon lysine residues affecting histone-DNA and histone-non-histone protein interactions.
- Histone deacetylases HDACs catalyze the deacetylation of histone and non-histone proteins and play an important role in epigenetic regulation.
- HDAC1 HDAC1 , HDAC2, HDAC3, HDAC8 and HDAC1 1
- HDAC4 HDAC5
- HDAC6, HDAC7, HDAC9 and HDAC10 which shuttle between the nucleus and the cytoplasm
- SIRT1-7 class III HDACs
- Class II HDACs are further characterized as class lla HDACs and class lib HDACs.
- HDAC9 is a class lla histone deacetylase highly expressed in human Tregs.
- HDAC9 deficiency 1 ) increases Foxp3 expression (and other Treg markers), 2) increases Foxp3 and histone 3 acetylation, 3) increases Foxp3 DNA binding, 4) increases Treg numbers, 5) increases suppressive activity in vitro and in vivo, and 6) ameliorates murine colitis.
- Tregs which are deficient in HDAC9 induce permanent tolerance of fully mismatched cardiac allografts.
- HDAC9 inhibitors maybe useful for treatment of diseases and disorders associated with abnormal cell proliferation, differentiation and survival, e.g. breast and prostate tumors.
- HDAC7 a class lla histone deacetylase
- HDAC7 enhances Treg suppression in vitro and in vivo.
- HDAC7 enhances FOXP3+ Treg function and induces long-term allograft survival.
- HDAC6 inhibition in vivo decreased severity of colitis in the dextran sodium sulphate-induced colitis model and the
- CD4 + CD62Lhigh adoptive transfer model of colitis In addition, inhibition of HDAC6 with a subtherapeutic dose of rapamycin led to prolonged cardiac allograft survival.
- an orally available small molecule selective inhibitor of Class II HDAC activity (more specifically HDAC9 or HDAC7 or HDAC6) is expected to modulate autoimmune diseases through expansion and enhancement of Treg activity.
- HDAC4 and 5 impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes and maybe potentially useful for the treatment of muscle and heart diseases including cardiac hypertrophy and heart failure. Also, inhibition of Class II HDAC activity, represents a novel approach for disrupting or intervening in cell cycle regulation.
- HDAC9 is also highly expressed in human B cells. Relative to normal B cells, expression of HDAC9 is deregulated in cell lines derived from B cell tumors and HDAC9 is highly overexpressed in cells derived from patients with non-Hodgkin's lymphoma (http://icr.ac.uk/research/team leaders/Zelent Arthur/Zelent Arthur Rl/index.shtml). HDAC4 and HDAC9 have both been reported to be overexpressed in CD19+ cells from patients with Waldenstrom Macroglobulinemia (Sun et al., Clinical Lymphoma, Myeloma & Leukemia, 201 1 , p. 152)
- Class Ma HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) have been reported to associate with Bcl-6, a transcription factor implicated in the pathogenesis of B-cell malignancies (Lemercier et al, Journal of Biological Chemistry, 2002, p. 22045, and Petrie et al, Journal of Biological Chemistry, 2003, p. 16059). Due to these interactions class lla HDACs have been suggested to modulate the transcriptional repression of BCL6 and participate in its role in B-cell activation and differentiation, inflammation, and cell-cycle regulation (Verdin et al. TRENDS in Genetics, 2003, p. 286) .
- HDAC6 a class lib HDAC, has been reported to play an important role in aggresomal protein degradation, making it a target for the treatment of B cell
- HDAC4 a small molecule selective inhibitor of HDAC4, HDAC5, HDAC6, HDAC7, HDAC8 and/or HDAC9 is expected to be beneficial in the treatment of B-cell malignancies by targeting one or several of the above enzymes
- HDAC4 has been linked to a variety of neurodegenerative disorders: it is a downstream target of Parkin (associating it to Parkinson's disease); it is a major component of intranuclear inclusions produced in NIIND. HDAC4 also contains a conserved glutamine rich domain, such domain has been observed to increase susceptibility to amyloid formation associated with Alzheimer's disease (Majdzadeh et al. Front. Biosci., 2009, p. 1072). Heterozygotes of HDAC4 knockouts crossed to R6/2 mice (Huntington's disease model) led to improved motor/behavior and reduced aggregation
- HDAC4 and HDAC5 localization are regulated by neuronal activity, and HDAC5 nuclear import is increased in diseased neurons of Huntington's disease patients.
- HDAC7 has been implicated in regulating ataxin-7 turnover in a SCA-7 model (Mookerjee S et al., J Neurosci., 2009, p. 15134).
- HDAC6 is expressed in most neurons and most abundantly in cerebellar Purkinje cells; the degeneration of this type of neurons is observed in patients with spinocerebellar ataxia type 1 (SCA1 ) or SCA7. HDAC6 is involved in regulating microtubule dynamics and protein degradation and a defect in microtubule-based transport may contribute to the neuronal toxicity observed in Huntington's disease (Kazantsev et al. Nature Reviews Drug Discovery, 2008, p. 854). Additionally, HDAC6 activity has been shown to be required for autophagic degradation of aggregated huntingtin, suggesting a role in protecting cells from polyQ toxicity (Iwata, et al., J. Biol. Chem., 2005, p. 40282).
- HDAC4 or HDAC5 or HDAC6 or HDAC7or HDAC9 is expected to be beneficial in the treatment of neurodegenerative diseases.
- Class II HDAC inhibitors have therapeutic potential in the study and/or treatment of the various diseases or conditions described herein.
- HDAC inhibitors Many of the known small-molecule HDAC inhibitors, however, inhibit all HDAC isoforms. It would be advantageous to identify HDAC inhibitors that inhibited one or more, but not all HDAC isoforms.
- the invention is directed to a compound according to Formula I:
- Ar is an optionally substituted aryl or heteroaryl group, wherein said aryl or heteroaryl is optionally substituted by 1-3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, (CrC 6 )alkyl, halo(CrC 6 )alkyl, (Ci-C 6 )alkoxy, aryloxy, halo(CrC 6 )alkoxy, (CrC 6 )alkylthio-, halo(Ci-C 6 )alkylthio-, hydroxy(C 1 -C 6 )alkyl-, amino, (C 1 -C 6 )alkylamino-, ((C 1 -C 6 )alkyl)((C 1 -C 6 )alkyl)amino-, -S0 2 NH 2 , -S0 2 NH(C C 6 )alkyl, -S0 2 N((Ci
- optionally substituted aryl is an optionally substituted 6, 9-10 or 13-14 membered aryl
- optionally substituted heteroaryl is an optionally substituted 5-6, 9-10 or 13-14 membered heteroaryl group and wherein said 5-6 membered
- heterocycloalkyl 5-6, 9-10 or 13-14 membered heteroaryl contains 1-4 hetereoatoms each independently selected from the group consisting of nitrogen, oxygen, and sulfur;
- X is -S0 2 -, -S0 2 NR 2 - or -NR 2 S0 2 -;
- R is an optionally substituted aryl, heteroaryl, (C 3 -C 6 )cycloalkyl, 3-6 membered heterocycloalkyl, aryl(Ci-C 4 )alkyl-, heteroaryl(Ci-C 4 )alkyl-,
- aryl, heteroaryl, cycloalkyl, or heterocycloalkyl that is the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group or the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl moiety of the aryl(Ci-C 4 )alkyl-, heteroaryl(Ci-C 4 )alkyl-,
- heteroaryl-(C 3 -C 6 )cycloalkyl-, aryl-(C 5 -C 6 )cycloalkenyl-, or heteroaryl-(C 5 -C 6 )cycloalkenyl- group) is optionally substituted by 1-3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, nitro, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (Ci-C 6 )alkoxy, phenoxy-, halo(CrC 6 )alkoxy, (CrC 6 )alkylthio-, halo(Ci-C 6 )alkylthio-, hydroxy(CrC 6 )alkyl-, amino, (Ci-C 6 )alkylamino-, ((Ci-C 6 )alkyl)((Ci-C 6 )alkyl)amino-, amino-
- optionally substituted aryl is an optionally substituted 6 or 9-10 membered aryl
- optionally substituted heteroaryl is an optionally substituted 5-6 or 9-10 membered heteroaryl group
- said 5-6 membered heterocycloalkyl
- 5-6-membered heteroaryl, or 9-10 membered heteroaryl contains 1 -4 hetereoatoms each independently selected from the group consisting of nitrogen, oxygen, and sulfur;
- R 2 is hydrogen, (d-C 6 )alkyl, aryl, aryl(CrC 4 )alkyl-, or 4-6 membered
- a pharmaceutical composition comprising the compound of Formula I, or a salt thereof, a method of inhibiting HDAC by contacting a HDAC with the compound of Formula I or a salt thereof, and a method of treating a subject having a disease or disorder mediated by inhibition of a HDAC comprising administering the compound of Formula I, or a salt thereof, or a pharmaceutical composition comprising the compound of Formula I, or a salt thereof, to the subject.
- the invention is further directed to a pharmaceutical composition comprising a compound of the invention.
- the invention is still further directed to methods of inhibiting HDAC enzymes and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
- alkyl represents a saturated, straight or branched hydrocarbon moiety.
- exemplary alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, f-butyl, n-pentyl, iso-pentyl (3-methyl- butyl), neo-pentyl (2,2-dimethylpropyl), etc.
- Ci-C 4 refers to an alkyl containing from 1 to 4 carbon atoms.
- alkyl When the term “alkyl” is used in combination with other substituent groups, such as “haloalkyl” or “cycloalkyl-alkyl” or “arylalkyl”, the term “alkyl” is intended to encompass a divalent straight or branched-chain hydrocarbon radical.
- arylalkyl is intended to mean the radical -alkylaryl, wherein the alkyl moiety thereof is a divalent straight or branched-chain carbon radical and the aryl moiety thereof is as defined herein, and is represented by the bonding arrangement present in a benzyl group (-CH 2 -phenyl).
- cycloalkyl refers to a non-aromatic, saturated, cyclic hydrocarbon ring.
- (C 3 -C 8 )cycloalkyl refers to a non-aromatic cyclic hydrocarbon ring having from three to eight ring carbon atoms.
- Exemplary "(C 3 -C 8 )cycloalkyl” groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- cycloalkenyl refers to a non-aromatic, partially unsaturated, cyclic hydrocarbon ring.
- exemplary (C 3 -C 8 )cycloalkenyll groups include, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl,
- Alkoxy refers to a group containing an alkyl radical attached through an oxygen linking atom.
- (Ci-C 4 )alkoxy refers to a straight- or branched-chain
- hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom.
- exemplary "(Ci-C 4 )alkoxy" groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, and f-butoxy.
- Aryl represents a group or moiety comprising an aromatic, monocyclic . , bicyclic or tricyclic hydrocarbon radical containing from 6 to 14 (generally, 6, 9-10, or 13-14) carbon ring atoms, wherein at least one ring of the group or moiety is aromatic.
- aryl groups include phenyl, naphthyl, indenyl, indanyl (dihydroindenyl), dihydronaphthyl, tetrahydronaphthyl, and fluorenyl.
- aryl is phenyl.
- Heterocyclic groups may be heteroaryl or heterocycloalkyl groups.
- Heterocycloalkyl represents a group or moiety comprising a stable
- heterocycloalkyl includes groups that might otherwise be called “heterocycloalkenyl.”
- the heterocycloalkyl may be attached by any atom of the monocyclic or bicyclic radical which results in the creation of a stable structure.
- This term encompasses bicyclic heterocycloalkyl moieties where the rings are joined at two atoms per ring, as exemplified by the bonding arrangement in 2,5- diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 2-oxa-5-azabicyclo[2.2.1 ]heptyl, 7- oxa-2-azabicyclo[2.2.1 ]heptyl, 2-thia-5-azabicyclo[2.2.1 ]heptyl,7-azabicyclo[2.2.1]heptyl, 2,6-diazatricyclo[3.3.1 .13,7]decyl, 2-azatricyclo[3.3.1 .13,7]decyl, 2,4,9- triazatricyclo[3.3.1.13,7]decyl, 8-azabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2- azabicyclo
- This term specifically excludes bicyclic heterocycloalkyl moieties where the rings are joined at a single atom per ring (spiro), as exemplified by the bonding arrangement in a 1-oxa-2-azaspiro[4.5]dec-2-en-3-yl group.
- heterocycloalkyls include, but are not limited to, azetidinyl, pyrrolidyl (or pyrrolidinyl), piperidinyl, piperazinyl, morpholinyl, tetrahydro-2H-1 ,4-thiazinyl, tetrahydrofuryl (or tetrahydrofuranyl), dihydrofuryl, oxazolinyl, thiazolinyl, pyrazolinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3-dioxolanyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3-oxathiolanyl, 1 ,3-oxathianyl, 1 ,3-dithianyl, azabicylo[3.2.1]octyl, azabicylo[3.3.1]non
- heterocycloalkyl groups are
- 5-membered and/or 6-membered heterocycloalkyl groups such as pyrrolidyl (or pyrrolidinyl), tetrahydrofuryl (or tetrahydrofuranyl), dihydrofuryl, tetrahydrothienyl, oxazolinyl, thiazolinyl, pyrazolinyl, piperidyl (or piperidinyl), piperazinyl, morpholinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3-dioxanyl, tetrahydro-2H-1 ,4-thiazinyl, 1 ,4-dioxanyl, 1 ,3-oxathianyl, and 1 ,3-dithianyl.
- pyrrolidyl or pyrrolidinyl
- tetrahydrofuryl or tetrahydrofuranyl
- dihydrofuryl te
- Heteroaryl represents a group or moiety comprising an aromatic, monocyclic, bicyclic or tricyclic radical, containing 5 to 14 (generally, 5-6, 9-1 1 or 13-14) ring atoms, including 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
- the bicyclic and tricyclic heteroaryl groups or moieties may contain an aromatic carbocyclic ring moiety (e.g., a phenyl) fused to a heterocycloalkyl ring moiety, or an aromatic heterocyclic ring moiety (e.g., a pyridyl or quinolyl ring moiety) fused to a cycloalkyl/cycloalkenyl ring moiety.
- heteroaryls include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl (or furanyl), isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyridyl (or pyridinyl), pyridyl-N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, benzo[b]thienyl, isobenzofuryl, 2,3-dihydrobenzofuryl, chromenyl, chromanyl, indolizinyl, iso
- benzothiazolyl benzimidazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, isoindolinyl, indolinyl, cinnolinyl, pteridinyl, carbazolyl, acridinyl, and isothiazolyl.
- heteroaryl groups present in the compounds of this invention are 5-6 membered monocyclic heteroaryl groups.
- Selected 5-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms.
- Selected 6-membered heteroaryl groups contain 1 , 2, 3 or 4 nitrogen ring heteroatoms.
- Selected 5- or 6-membered heteroaryl groups include thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, triazolyl, and tetrazolyl or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and thiadiazolyl.
- Some of the heteroaryl groups present in the compounds of this invention are 9-10 membered bicyclic heteroaryl groups.
- Selected 9-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms.
- Selected 10-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, 3 or 4 additional nitrogen ring atoms.
- Selected 9-10 membered heteroaryl groups include benzo[b]thienyl, isobenzofuryl, 2,3-dihydrobenzofuryl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl,
- Selected 13-14 membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, 3 or 4 additional nitrogen ring atoms.
- 13-membered heteroaryl group is carbazolyl.
- a representavtive 14-membered heteroaryl group is acridinyl.
- alkyl, aryl, cycloalkyl, heteroaryl, etc. may be used to define a divalent substituent, such as a group bonded to two other groups. In this instance, such terms are intended to encompass divalent moieties.
- pentyl may be used to represent a pentylenyl diradical -wherein the pentyl moiety is any one of a divalent straight (e.g. -CH 2 CH 2 CH 2 CH 2 CH 2 -) or branched (e.g. -CH 2 CH(CH 3 )CH 2 CH 2 -,
- Haldroxy or “hydroxyl” is intended to mean the radical -OH.
- Ar is an optionally substituted aryl, 5-6 or 9-14 membered heteroaryl group, optionally substituted by 1 -2 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, (Ci-C 6 )alkyl, aryl, heteroaryl, halo(CrC 6 )alkyl, (d-C 6 )alkoxy, halo(CrC 6 )alkoxy, aryloxy (Ci-C 6 )alkylthio-, halo(CrC 6 )alkylthio-, hydroxy(CrC 6 )alkyl-, amino, (Ci-C 6 )alkylamino-, ((Ci-C 6 )alkyl)((Ci-C 6 )alkyl)amino- heterocycloalkyl, -S0 2 NH 2 , -S0 2 NH(Ci-C 6 )
- Ar is an optionally substituted phenyl, pyridyl, furyl, indolyl, pyrrolyl, imidazolyl, naphthyl, quinolyl, benzimidazolyl,
- Ar is an optionally substituted phenyl optionally substituted by a substituent selected from the group consisting of halo, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, and halo(C 1 -C 6 )alkoxy.
- Ar is an unsubstituted phenyl.
- X is -S0 2 NH- and has the bonding arrangement
- R is an optionally substituted 6, 9, or 10 membered aryl group, an optionally substituted 5, 6, 9 or 10 membered heteroaryl group, an optionally substituted 6, 9 or 10 membered aryl(Ci-C 4 )alkyl- group, an optionally substituted 5, 6, 9 or 10 membered heteroaryl(Ci-C 4 )alkyl- group, an optionally substituted 6, 9 or 10 membered aryl(C 2 -C 4 )alkenyl- group, or an optionally substituted 5, 6, 9 or 10 membered heteroaryl(C 2 -C 4 )alkenyl- group,
- any of said aryl or heteroaryl (that is the aryl or heteroaryl group or the aryl or heteroaryl moiety of the aryl(Ci-C 4 )alkyl-, heteroaryl(Ci-C 4 )alkyl-,
- aryl(C 2 -C 4 )alkenyl- or heteroaryl(C 2 -C 4 )alkenyl- group) is optionally substituted by 1-2 substituents each independently selected from the group consisting of halo, hydroxy, (Ci-C 4 )alkyl, halo(CrC 4 )alkyl, (d-C 4 )alkoxy, phenoxy-, halo(Ci-C 4 )alkoxy,
- heteroaryl(Ci-C 4 )alkyl-, aryl(C 2 -C 4 )alkenyl-, or heteroaryl(C 2 -C 4 )alkenyl-, is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen, hydroxyl, (CrC 4 )alkoxy, phenyl, (Ci-C 4 )alkylCO-, and oxo.
- R is an optionally substituted phenyl, naphthyl, imidazolyl, pyridyl, furanyl, indenyl, dihydroindenyl, quinolyl, benzimidazolyl, or indolyl.
- R is optionally substituted by 1 , 2 or 3 independently selected R 1 substituents.
- R is phenyl group, substituted by 0, 1 or 2 independently selected R 1 substituents.
- each R 1 substituent is independently selected from the group consisting of fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, nitro, -S0 2 NH 2 , and phenyl.
- R is a substituted phenyl group selected from the group consisting of: 4-(fluoro)phenyl, 4-(chloro)phenyl, 4-(bromo)phenyl, 4-(iodo)phenyl, 4-(methyl) phenyl, 4-(ethyl)phenyl, 4-(isopropyl)phenyl, 4-(t-butyl)phenyl, 4-(cyano)phenyl, 4-(trifluoromethyl)phenyl, 4-(hydroxy)phenyl, 4-(methoxy)phenyl, 4-(ethoxy)phenyl, 4-(isopropoxy)phenyl, 4-(trifluoromethoxy)phenyl, 4-(difluoromethoxy)phenyl,
- R is a substituted phenyl group selected from the group consisting of: 3,4-di(methoxy)phenyl, 3,4-di(hydroxy)phenyl, 3,4-di(methyl)phenyl, 3,4-di(fluoro)phenyl, 3-(chloro), 4-(fluoro)phenyl, 2,4-di(chloro)phenyl, 2,4-di(fluoro)phenyl,
- R 2 is hydrogen, (C 1 -C 6 )alkyl or aryl. In another embodiment, R 2 is H or (CrC 4 )alkyl. In another embodiment R 2 is H, methyl or ethyl.
- the invention is directed to a compound according to Formula (l-a):
- n is 0, 1 , 2, or 3, specifically n is 0, 1 , or 2, and more specifically, n is 0 or1 ; and each R 1 is independently selected from the group consisting of fluoro, chloro, bromo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino, dimethylamino, diethylamino, morpholino, -CONH 2 , -COCH 3 , nitro, -S0 2 NH 2 , and phenyl, or a salt thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
- n is 0.
- the terms "compound(s) of the invention” or “compound(s) of this invention” mean a compound of Formula (I), as defined above, in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly a
- any physical form thereof e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
- non-solid forms e.g., liquid or semi-solid forms
- solid forms e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)
- mixtures of various forms e.g., including hydrate forms (e.g., mono-, di- and hemi- hydrates)
- optionally substituted means unsubstituted groups or rings (e.g., cycloalkyl, heterocycle, and heteroaryl rings) and groups or rings substituted with one or more specified substituents.
- the compounds according to Formula I may contain one or more asymmetric center (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof.
- Chiral centers such as chiral carbon atoms, may also be present in a substituent such as an alkyl group.
- the stereochemistry of a chiral center present in Formula I, or in any chemical structure illustrated herein, is not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof.
- compounds according to Formula I containing one or more chiral centers may be used as racemic mixtures, scalemic mixtures, or as diaseteromerically or enantiomerically pure materials.
- Individual stereoisomers of a compound according to Formula I which contain one or more asymmetric center may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1 ) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer- specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
- stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
- polymorphism i.e. the capacity to occur in different crystalline forms. These different crystalline forms are typically known as "polymorphs.” It is to be understood that when named or depicted by structure, the disclosed compound, or solvates (particularly, hydrates) thereof, also include all polymorphs thereof. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
- Formula I are preferably pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse,
- salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention.
- a salt may be readily prepared by using a desired acid or base as appropriate.
- the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
- a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, and the like, or with a pyranosidyl acid, such as glucuronic acid or galacturonic acid, or with an alpha-hydroxy acid, such as citric acid or tartaric acid, or with an amino acid, such as aspartic acid or glutamic acid, or with an aromatic acid, such as benzoic acid or cinnamic acid, or with a sulfonic acid, such as
- Suitable addition salts are formed from acids which form non-toxic salts and examples include acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, calcium edetate, camsylate, carbonate, clavulanate, citrate, cyclohexylsulfamate, edetate, edisylate, estolate, esylate, ethanedisulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, dihydrochloride, hydrofumarate, hydrogen phosphate, hydroiodide, hydromaleate, hydrosuccinate, hydroxyn
- exemplary acid addition salts include pyrosulfate, sulfite, bisulfite, decanoate, caprylate, acrylate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, suberate, sebacate, butyne-1 ,4-dioate, hexyne-1 ,6-dioate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, phenylacetate, phenylpropionate, phenylbutrate, lactate, ⁇ -hydroxybutyrate, mandelate, and sulfonates, such as xylenesulfonate, propanesulfonate, naphthalene-1 -sulfonate and naphthalene-2-sulfonate.
- an inventive basic compound is isolated as a salt
- the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pK a than the free base form of the compound.
- a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
- an inorganic or organic base such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
- suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine, as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
- amino acids such as glycine and arginine
- ammonia such as glycine and arginine
- primary, secondary, and tertiary amines such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine
- Certain of the compounds of this invention may form salts with one or more equivalents of an acid (if the compound contains a basic moiety) or a base (if the compound contains an acidic moiety).
- the present invention includes within its scope all possible stoichiometric and non-stoichiometric salt forms.
- Compounds of the invention having both a basic and acidic moiety may be in the form of zwitterions, acid-addition salt of the basic moiety or base salts of the acidic moiety.
- This invention also provides for the conversion of one pharmaceutically acceptable salt of a compound of this invention, e.g., a hydrochloride salt, into another
- a pharmaceutically acceptable salt of a compound of this invention e.g., a sulfate salt.
- solvates of the compounds of Formula I, or salts thereof that are in crystalline form may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization.
- Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice.
- Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as
- Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water.
- the invention includes all such solvates.
- the compounds of Formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.
- the compounds of this invention may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist.
- the synthesis provided in these Schemes are applicable for producing compounds of the invention having a variety of different R 1 and R 2 groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula I, they are illustrative of processes that may be used to make the compounds of the invention.
- Specific compounds of this invention are the compounds of Examples 1 -2, including salts, particularly pharmaceutically acceptable salts, thereof.
- ChemDraw 1 1.0 available from CambridgeSoft Corporation., 100 CambridgePark Drive,
- the compounds of Formula I can be prepared according to the methods outlined below.
- a halo-(hetero)aryl sulfonyl chloride may be treated with an amine (NH 2 R 2 ) to provide a halo-substituted (hetero)arylsulfonamide.
- This sulfonamide may be treated with cyano-ethylene, palladium on carbon, tri-otolylphospine, potassium acetate and tetrabutylammonium chloride to provide the homologated (hetero)arylsulfonamide, which may be treated with hydroxylamine, followed by trifluoroacetic anhydrideto provide the target oxadiazolyl compounds.
- the invention also includes various deuterated forms of the compounds of Formula I.
- Each available hydrogen atom attached to a carbon atom may be
- deuterated alkyl groups e.g., /V-(deutero-methyl) amines
- deuterated alkyl groups may be prepared by
- the present invention is directed to a method of inhibiting an HDAC which comprises contacting the acetylase with a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. More specifically, this invention is directed to a method of inhibiting HDAC comprising contacting a cell with an effective amount of a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. This invention is also directed to a method of treatment of an HDAC-mediated disease or disorder comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof. As used herein, "patient” refers to a mammal, specifically, a human. A therapeutically "effective amount” is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein.
- pharmaceutically acceptable salt thereof is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to inhibit the activity of HDAC such that a disease condition which is mediated by that activity is reduced, alleviated or prevented.
- the amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pXC 5 o), efficacy (EC5 0 ), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
- duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or condition and its severity and the specific composition and method being used, but can
- Treating is intended to mean at least the mitigation of a disease condition in a patient, where the disease condition is caused or mediated by HDAC.
- the methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a disease.
- this invention is directed to a method of treating, ameliorating, or preventing an autoimmune disorder, an immunological disease, an inflammatory disorder, transplant/graft rejection (e.g., allograft), lymphopenia, or graft-versus-host disease (GvHD) in a patient, specifically in a human, comprising administering to the patient a compound of this invention, in an amount sufficient to increase the level and/or activity of a Treg cell or a population of Treg cells in the patient, thereby treating, ameliorating, or preventing the autoimmune disorder, inflammatory disorder,
- transplant/graft rejection e.g., allograft
- lymphopenia e.g., allograft
- GvHD graft-versus-host disease
- transplant/graft rejection transplant/graft rejection, lymphopenia, or GvHD in the patient.
- diseases and conditions that may be treated by the compounds of this invention include but not limited to type II diabetes mellitus, coronary artery disease, alopecia, allergies and allergic reactions, and sepsis/toxic shock.
- Exemplary autoimmune disorders include, but are not limited to, multiple sclerosis, juvenile idiopathic arthritis, psoriatic arthritis, hepatitis C virus-associated mixed cryoglobulinemia, polymyositis, dermatomyositis, polyglandular syndrome type II, autoimmune liver disease, Kawasaki disease, myasthenia gravis, immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX (syndrome)), type I diabetes, psoriasis, hypothyroidism, hemolytic anemia, autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy (APECED), thrombocytopenia, spondyloarthritis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, eczema, gastritis, or thyroiditis.
- the inflammatory bowel disease IBD
- autoimmune diseases include osteoarthritis, systemic sclerosis, sarcoidosis, insulin dependent diabetes mellitus (IDDM, type I diabetes), reactive arthritis, scleroderma, vasculitis, Wegener's granulomatosis, Hashimoto's disease, scleroderma, oophoritis, Lupus (SLE), Grave's disease, asthma, cryoglobulinemia, primary biliary sclerosis, pemphigus vulgaris, hemolytic anemia and pernicious anemia.
- IDDM insulin dependent diabetes mellitus
- SLE oophoritis
- Grave's disease asthma, cryoglobulinemia, primary biliary sclerosis, pemphigus vulgaris, hemolytic anemia and pernicious anemia.
- transplant/graft rejection e.g., allograft
- lymphopenia e.g., lymphopenia
- graft- versus-host disease e.g., graft- versus-host disease
- transplant/graft rejection e.g., allograft
- lymphopenia e.g., lymphopenia
- graft- versus-host disease e.g., graft- versus-host disease
- transplant/graft rejection e.g., allograft
- lymphopenia e.g., lymphopenia
- GvHD graft- versus-host disease
- this invention is directed to a method of treating an HDAC-mediated neurodegenerative disease or disorder which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
- This invention is also directed to a method of treatment of a neurodegenerative disease or disorder associated with deacetylases, such as, Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion disease (NMD), and polyglutamine disorders, such as Huntington's disease and spinocerebellar ataxia (SCA), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
- deacetylases such as, Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion disease (NMD), and polyglutamine disorders, such as Huntington's disease and spinocerebellar ataxia (SCA)
- diseases and conditions include but are not limited to cystic fibrosis, osteoporosis, obesity, epilepsy, depression, thalassemia, sickle cell anemia, amyotrophic lateral sclerosis (ALS) and hyperalgesia, cardiac disease (e.g., stroke, hypertension, atherothrombotic diseases, artherosclerosis or limitation of infarct size in acute coronary syndrome), diseases or disorders involving muscular atrophy, gentamicin-induced hearing loss, drug resistance (e.g., drug resistance in osteosarcoma and colon cancer cells), infectious diseases, and immune deficiency/immunocompromised patients.
- cystic fibrosis e.g., osteoporosis
- obesity e.g., epilepsy, depression, thalassemia, sickle cell anemia, amyotrophic lateral sclerosis (ALS) and hyperalgesia
- cardiac disease e.g., stroke, hypertension, atherothrombotic diseases, artherosclerosis or limitation
- infectious diseases relate to various pathogen infections such as viral, fungal, bacterial, mycoplasm, and infections by unicellular and multicellular eukaryotic organisms.
- pathogens include but are not limited to HIV, HSV, HPV, Hepatitis A, B and C viruses, influenza, denge, zostrella, rubella, RSV, rotavirus, gram positive, gram negative, streptococcus, tetanus, staphalococcus, tuberculosis, listeria, and malaria.
- the compounds of the invention may be employed alone or in combination with standard anti-cancer regimens for neoplastic cell, e.g., tumor cell and cancer cell, treatments.
- this invention is directed to inhibitors of HDAC and their use to stop or reduce the growth of neoplastic cells, e.g., cancer cells and tumor cells.
- carcinoma e.g., adenocarcinoma
- heptaocellular carcinoma e.g., sarcoma
- myeloma e.g., multiple myeloma
- treating bone disease in multiple myeloma leukemia, childhood acute lymphoblastic leukemia and lymphoma (e.g., cutaneous cell lymphoma)
- mixed types of cancers such as adenosquamous carcinoma, mixed mesodermal tumor, carcinosarcoma, and teratocarcinoma.
- breast or prostate cancers or tumors are treated using the HDAC inhibitors of this invention.
- Other cancers that may be treated using the compounds of this invention include, but are not limited to, bladder cancer, breast cancer, prostate cancer, stomach cancer, lung cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, endometrial cancer, pancreatic cancer, cervical cancer, ovarian cancer; head and neck cancer, and melanoma.
- the present invention is further directed to a method of treating a B-cell lymphoma, particularly a B-cell lymphoma associated with deacetylases, which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof.
- B-cell lymphomas associated with deacetylases include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and
- this invention is directed to a method of treatment of Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and Waldenstrom Macroglobulinemia (lymphoplasmacytic lymphoma), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
- CLL/SLL chronic lymphocytic leukemia/small lymphocytic lymphoma
- follicular lymphoma immunoblastic large cell lymphoma
- precursor B-lymphoblastic lymphoma precursor B-lymphoblastic lymphoma
- mantle cell lymphoma mantle cell lymphoma
- the compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
- Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
- Parenteral administration refers to routes of administration other than enteral
- transdermal, or by inhalation and is typically by injection or infusion.
- Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
- Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
- Topical administration includes application to the skin.
- the compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect.
- Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan.
- suitable dosing regimens, including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
- Treatment of HDAC-mediated disease conditions may be achieved using the compounds of this invention as a monotherapy, or in dual or multiple combination therapy, such as in combination with other agents, for example, in combination with one or more of the following agents: DNA methyltransferase inhibitors, acetyl transferase enhancers, proteasome or HSP90 inhibitors, and one or more immunosuppressants that do not activate the T suppressor cells including but are not limited to corticosteroids, rapamycin, Azathioprine, Mycophenolate, Cyclosporine, Mercaptopurine (6-MP), basiliximab, daclizumab, sirolimus, tacrolimus, Muromonab-CD3, cyclophosphamide, and
- methotrexate which are administered in effective amounts as is known in the art.
- the compounds of the invention will normally, but not necessarily, be formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically-acceptable excipient.
- compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection.
- the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form.
- a dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula I or a salt, particularly a pharmaceutically acceptable salt, thereof).
- the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
- compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
- pharmaceutically-acceptable excipient means a material, composition or vehicle involved in giving form or consistency to the composition.
- Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically-acceptable are avoided.
- each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
- the compounds of the invention and the pharmaceutically-acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration.
- Conventional dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
- Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen.
- suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition.
- certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
- Certain pharmaceutically- acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
- Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
- Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
- Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
- excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants,
- Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention.
- resources that are available to the skilled artisan which describe pharmaceutically-acceptable excipients and may be useful in selecting suitable pharmaceutically-acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
- compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing
- the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler.
- Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
- the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
- the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
- the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
- 3-Bromo-W-phenylbenzenesulfonamide 3-Bromobenzene-1-sulfonyl chloride (1 .02 g, 4.0 mmol) was added to a stirring solution of aniline (0.365 mL, 4.0 mmol) and Et 3 N (0.84 mL, 6.0 mmol) in DCM (25 mL). The reaction mixture was allowed to stir 3 h. The reaction mixture was concentrated under reduced pressure and purified by silica gel
- Tablets are prepared using conventional methods and are formulated as follows:
- Capsules are prepared using conventional methods and are formulated as follows
- HDAC9 Histone Deacetylase 9
- Novel histone deacetylase 9 (HDAC9) inhibitors were characterized in an in vitro biochemical functional assay.
- the assay measures the increased fluorescent signal due to deacetylation, by HDAC9, of a fluorogenic substrate.
- the commercial available substrate is Class lla HDAC-specific and contains an acetylated lysine residue and would releases the fluorescent signal upon trypsin cleavage after deacetylation.
- test compounds diluted to various concentrations in 100% DMSO are first dispensed into 384-well assay plates.
- Recombinant HDAC9 isoform 4 (purchased from BPS Bioscience) in complete assay buffer (50 mM Tris-HCI, pH 8.0, 137 mM NaCI, 2.7 mM KCI, 1 mM MgCI 2 , 0.05% BSA & 0.005% Tween 20) were then added to each well (5uL/well) using Multidrop Combi (Thermo Scientific), followed by 5 uL/well substrate (purchased from BPS Bioscience, 4.5 uM final).
- plC 50 s For concentration/dose response experiments, normalized data were fit and plC 50 s determined using conventional techniques. The plC 50 s are averaged to determine a mean value, for a minimum of 2 experiments. As determined using the above method, the compounds of Examples 1-2 exhibited a plC 50 between 5.0 and 9.0, for example, the compound of Example 2 inhibited HDAC9 in the above method with a mean plC 50 > 5.5.
- HDAC7 targeting enhances FOXP3+ Treg function and induces long-term allograft survival L. Wang, et al., Am. J. Transplant 9, S621 (2009).
Abstract
Disclosed are compounds having the formula (I), wherein Ar, X, and R are as defined herein, and methods of making and using the same.
Description
COMPOUNDS AND METHODS
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to compounds that inhibit histone deacetylase
(HDAC) enzymes, the preparation of these compounds, the use of these compounds in the treatment of diseases or conditions ameliorated by inhibition of HDAC activity and pharmaceutical compositions comprising these compounds. Background of the Invention
Chromatin organization involves DNA wound around histone octamers that form nucleosomes. Core histones with N-terminal tails extending from compact nucleosomal core particles can be acetylated or deacetylated at epsilon lysine residues affecting histone-DNA and histone-non-histone protein interactions. Histone deacetylases (HDACs) catalyze the deacetylation of histone and non-histone proteins and play an important role in epigenetic regulation. There are currently 18 known HDACs that are organized into three classes: class I HDACs (HDAC1 , HDAC2, HDAC3, HDAC8 and HDAC1 1 ) are mainly localized to the nucleus; class II HDACs (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10), which shuttle between the nucleus and the cytoplasm; and class III HDACs (SIRT1-7), whose cellular localization includes various organelles.
Class II HDACs are further characterized as class lla HDACs and class lib HDACs.
HDAC9 is a class lla histone deacetylase highly expressed in human Tregs. HDAC9 deficiency: 1 ) increases Foxp3 expression (and other Treg markers), 2) increases Foxp3 and histone 3 acetylation, 3) increases Foxp3 DNA binding, 4) increases Treg numbers, 5) increases suppressive activity in vitro and in vivo, and 6) ameliorates murine colitis. Tregs which are deficient in HDAC9 induce permanent tolerance of fully mismatched cardiac allografts. In addition, HDAC9 inhibitors maybe useful for treatment of diseases and disorders associated with abnormal cell proliferation, differentiation and survival, e.g. breast and prostate tumors.
Preliminary data shows that targeting HDAC7, a class lla histone deacetylase, enhances Treg suppression in vitro and in vivo. HDAC7 enhances FOXP3+ Treg function and induces long-term allograft survival.
Inhibition of HDAC6, a class lib HDAC, has been shown to increase Treg suppressive function in vitro along with increased expression of FOXP3 protein and Treg associated genes including CTLA, IL-10, TNR18. HDAC6 inhibition in vivo decreased
severity of colitis in the dextran sodium sulphate-induced colitis model and the
CD4+CD62Lhigh adoptive transfer model of colitis. In addition, inhibition of HDAC6 with a subtherapeutic dose of rapamycin led to prolonged cardiac allograft survival.
Thus, an orally available small molecule selective inhibitor of Class II HDAC activity (more specifically HDAC9 or HDAC7 or HDAC6) is expected to modulate autoimmune diseases through expansion and enhancement of Treg activity.
Inhibition of other Class II HDAC's for example HDAC4 and 5 impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes and maybe potentially useful for the treatment of muscle and heart diseases including cardiac hypertrophy and heart failure. Also, inhibition of Class II HDAC activity, represents a novel approach for disrupting or intervening in cell cycle regulation.
HDAC9 is also highly expressed in human B cells. Relative to normal B cells, expression of HDAC9 is deregulated in cell lines derived from B cell tumors and HDAC9 is highly overexpressed in cells derived from patients with non-Hodgkin's lymphoma (http://icr.ac.uk/research/team leaders/Zelent Arthur/Zelent Arthur Rl/index.shtml). HDAC4 and HDAC9 have both been reported to be overexpressed in CD19+ cells from patients with Waldenstrom Macroglobulinemia (Sun et al., Clinical Lymphoma, Myeloma & Leukemia, 201 1 , p. 152)
Class Ma HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) have been reported to associate with Bcl-6, a transcription factor implicated in the pathogenesis of B-cell malignancies (Lemercier et al, Journal of Biological Chemistry, 2002, p. 22045, and Petrie et al, Journal of Biological Chemistry, 2003, p. 16059). Due to these interactions class lla HDACs have been suggested to modulate the transcriptional repression of BCL6 and participate in its role in B-cell activation and differentiation, inflammation, and cell-cycle regulation (Verdin et al. TRENDS in Genetics, 2003, p. 286) .
HDAC6, a class lib HDAC, has been reported to play an important role in aggresomal protein degradation, making it a target for the treatment of B cell
malignancies (Simms-Waldrip et al., Molecular Genetics and Metabolism, 2008, p. 283)
Accordingly, a small molecule selective inhibitor of HDAC4, HDAC5, HDAC6, HDAC7, HDAC8 and/or HDAC9 is expected to be beneficial in the treatment of B-cell malignancies by targeting one or several of the above enzymes
HDAC4, HDAC5 and HDAC9 are also highly expressed in the brain. HDAC4 has been linked to a variety of neurodegenerative disorders: it is a downstream target of Parkin (associating it to Parkinson's disease); it is a major component of intranuclear inclusions produced in NIIND. HDAC4 also contains a conserved glutamine rich domain, such domain has been observed to increase susceptibility to amyloid formation
associated with Alzheimer's disease (Majdzadeh et al. Front. Biosci., 2009, p. 1072). Heterozygotes of HDAC4 knockouts crossed to R6/2 mice (Huntington's disease model) led to improved motor/behavior and reduced aggregation
(http://bmi.epfl.ch/files/content/sites/bmi/files/shared/Abstract Gillian Bates.pdD. HDAC4 and HDAC5 localization are regulated by neuronal activity, and HDAC5 nuclear import is increased in diseased neurons of Huntington's disease patients.
HDAC7 has been implicated in regulating ataxin-7 turnover in a SCA-7 model (Mookerjee S et al., J Neurosci., 2009, p. 15134).
HDAC6 is expressed in most neurons and most abundantly in cerebellar Purkinje cells; the degeneration of this type of neurons is observed in patients with spinocerebellar ataxia type 1 (SCA1 ) or SCA7. HDAC6 is involved in regulating microtubule dynamics and protein degradation and a defect in microtubule-based transport may contribute to the neuronal toxicity observed in Huntington's disease (Kazantsev et al. Nature Reviews Drug Discovery, 2008, p. 854). Additionally, HDAC6 activity has been shown to be required for autophagic degradation of aggregated huntingtin, suggesting a role in protecting cells from polyQ toxicity (Iwata, et al., J. Biol. Chem., 2005, p. 40282).
Accordingly, a small molecule selective inhibitor of HDAC activity (more
specifically HDAC4 or HDAC5 or HDAC6 or HDAC7or HDAC9) is expected to be beneficial in the treatment of neurodegenerative diseases.
Class II HDAC inhibitors have therapeutic potential in the study and/or treatment of the various diseases or conditions described herein.
Many of the known small-molecule HDAC inhibitors, however, inhibit all HDAC isoforms. It would be advantageous to identify HDAC inhibitors that inhibited one or more, but not all HDAC isoforms.
SUMMARY OF THE INVENTION
The invention is directed to a compound according to Formula I:
wherein:
Ar is an optionally substituted aryl or heteroaryl group, wherein said aryl or heteroaryl is optionally substituted by 1-3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, (CrC6)alkyl, halo(CrC6)alkyl, (Ci-C6)alkoxy, aryloxy, halo(CrC6)alkoxy, (CrC6)alkylthio-, halo(Ci-C6)alkylthio-,
hydroxy(C1-C6)alkyl-, amino, (C1-C6)alkylamino-, ((C1-C6)alkyl)((C1-C6)alkyl)amino-, -S02NH2, -S02NH(C C6)alkyl, -S02N((Ci-C6)alkyl)((Ci-C6)alkyl), -CO(d-C6)alkyl, -CONH2, -CONH(d-C6)alkyl, -CON((C1-C6)alkyl)((C1-C6)alkyl), aryl, heteroaryl, and 5-6 membered heterocycloalkyl,
wherein said optionally substituted aryl is an optionally substituted 6, 9-10 or 13-14 membered aryl, and said optionally substituted heteroaryl is an optionally substituted 5-6, 9-10 or 13-14 membered heteroaryl group and wherein said 5-6 membered
heterocycloalkyl, 5-6, 9-10 or 13-14 membered heteroaryl contains 1-4 hetereoatoms each independently selected from the group consisting of nitrogen, oxygen, and sulfur;
X is -S02-, -S02NR2- or -NR2S02-;
R is an optionally substituted aryl, heteroaryl, (C3-C6)cycloalkyl, 3-6 membered heterocycloalkyl, aryl(Ci-C4)alkyl-, heteroaryl(Ci-C4)alkyl-,
aryl(C2-C4)alkenyl-, heteroaryl(C2-C4)alkenyl-, aryl-(C3-C6)cycloalkyl-, heteroaryl- (C3-C6)cycloalkyl-, aryl-(C5-C6)cycloalkenyl-, or heteroaryl-(C5-C6)cycloalkenyl-,
wherein said aryl, heteroaryl, cycloalkyl, or heterocycloalkyl (that is the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group or the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl moiety of the aryl(Ci-C4)alkyl-, heteroaryl(Ci-C4)alkyl-,
aryl(C2-C4)alkenyl-, heteroaryl(C2-C4)alkenyl-, aryl-(C3-C6)cycloalkyl-,
heteroaryl-(C3-C6)cycloalkyl-, aryl-(C5-C6)cycloalkenyl-, or heteroaryl-(C5-C6)cycloalkenyl- group) is optionally substituted by 1-3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, nitro, (C1-C6)alkyl, halo(C1-C6)alkyl, (Ci-C6)alkoxy, phenoxy-, halo(CrC6)alkoxy, (CrC6)alkylthio-, halo(Ci-C6)alkylthio-, hydroxy(CrC6)alkyl-, amino, (Ci-C6)alkylamino-, ((Ci-C6)alkyl)((Ci-C6)alkyl)amino-, amino-(Ci-C6)alkyl-, (Ci-C6)alkylamino(Ci-C6)alkyl-,
((Ci-C6)alkyl)((Ci-C6)alkyl)amino(Ci-C6)alkyl-, -S02NH2, -S02NH(Ci-C6)alkyl,
-S02N((Ci-C6)alkyl)((Ci-C6)alkyl), -CONH2, -CONH(C C6)alkyl,
-CON((Ci-C6)alkyl)((Ci-C6)alkyl), -CO(C C6)alkyl, phenyl, and 5-6 membered
heterocycloalkyl,
and wherein the alkyl, alkenyl, cycloalkyl, or cycloalkenyl moieties of said aryl(Ci-C4)alkyl- , heteroaryl(Ci-C4)alkyl-, aryl(C2-C4)alkenyl- heteroaryl(C2-C4)alkenyl-, aryl-(C3-C6)cycloalkyl-, heteroaryl-(C3-C6)cycloalkyl-, aryl-(C5-C6)cycloalkenyl- and heteroaryl-(C5-C6)cycloalkenyl- is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, hydroxyl, (CrC4)alkoxy, aryl, (C C4)alkylCO-, ((C C4)alkyl)NHCO-, -CONH2, and oxo;
wherein said optionally substituted aryl is an optionally substituted 6 or 9-10 membered aryl, said optionally substituted heteroaryl is an optionally substituted 5-6 or
9-10 membered heteroaryl group, and said 5-6 membered heterocycloalkyl,
5-6-membered heteroaryl, or 9-10 membered heteroaryl contains 1 -4 hetereoatoms each independently selected from the group consisting of nitrogen, oxygen, and sulfur;
R2 is hydrogen, (d-C6)alkyl, aryl, aryl(CrC4)alkyl-, or 4-6 membered
heterocycloalkyl;
or a salt thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof, and is further directed to a pharmaceutical composition comprising the compound of Formula I, or a salt thereof, a method of inhibiting HDAC by contacting a HDAC with the compound of Formula I or a salt thereof, and a method of treating a subject having a disease or disorder mediated by inhibition of a HDAC comprising administering the compound of Formula I, or a salt thereof, or a pharmaceutical composition comprising the compound of Formula I, or a salt thereof, to the subject.
The invention is further directed to a pharmaceutical composition comprising a compound of the invention. The invention is still further directed to methods of inhibiting HDAC enzymes and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
DETAILED DESCRIPTION OF THE INVENTION
The alternative definitions for the various groups and substituent groups of Formula I provided throughout the specification are intended to particularly describe each compound species disclosed herein, individually, as well as groups of one or more compound species. The scope of this invention includes any combination of these group and substituent group definitions.
As used herein, the term "alkyl" represents a saturated, straight or branched hydrocarbon moiety. Exemplary alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, f-butyl, n-pentyl, iso-pentyl (3-methyl- butyl), neo-pentyl (2,2-dimethylpropyl), etc. The term "Ci-C4" refers to an alkyl containing from 1 to 4 carbon atoms.
When the term "alkyl" is used in combination with other substituent groups, such as "haloalkyl" or "cycloalkyl-alkyl" or "arylalkyl", the term "alkyl" is intended to encompass a divalent straight or branched-chain hydrocarbon radical. For example, "arylalkyl" is intended to mean the radical -alkylaryl, wherein the alkyl moiety thereof is a divalent straight or branched-chain carbon radical and the aryl moiety thereof is as defined herein, and is represented by the bonding arrangement present in a benzyl group (-CH2-phenyl).
As used herein, the term "cycloalkyl" refers to a non-aromatic, saturated, cyclic hydrocarbon ring. The term "(C3-C8)cycloalkyl" refers to a non-aromatic cyclic
hydrocarbon ring having from three to eight ring carbon atoms. Exemplary "(C3-C8)cycloalkyl" groups useful in the present invention include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
As used herein, the term "cycloalkenyl" refers to a non-aromatic, partially unsaturated, cyclic hydrocarbon ring. Exemplary (C3-C8)cycloalkenyll groups include, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl,
cycloheptenyl, and cyclooctadienyl.
"Alkoxy" refers to a group containing an alkyl radical attached through an oxygen linking atom. The term "(Ci-C4)alkoxy" refers to a straight- or branched-chain
hydrocarbon radical having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom. Exemplary "(Ci-C4)alkoxy" groups useful in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, and f-butoxy.
"Aryl" represents a group or moiety comprising an aromatic, monocyclic., bicyclic or tricyclic hydrocarbon radical containing from 6 to 14 (generally, 6, 9-10, or 13-14) carbon ring atoms, wherein at least one ring of the group or moiety is aromatic.
Exemplary aryl groups include phenyl, naphthyl, indenyl, indanyl (dihydroindenyl), dihydronaphthyl, tetrahydronaphthyl, and fluorenyl. Generally, in the compounds of this invention, aryl is phenyl.
Heterocyclic groups may be heteroaryl or heterocycloalkyl groups.
"Heterocycloalkyl" represents a group or moiety comprising a stable,
non-aromatic, monocyclic or bicyclic radical, which is saturated or partially unsaturated, containing 3 to 10 ring atoms, which includes 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. Thus, the term "heterocycloalkyl" includes groups that might otherwise be called "heterocycloalkenyl." The heterocycloalkyl may be attached by any atom of the monocyclic or bicyclic radical which results in the creation of a stable structure. This term encompasses bicyclic heterocycloalkyl moieties where the rings are joined at two atoms per ring, as exemplified by the bonding arrangement in 2,5- diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 2-oxa-5-azabicyclo[2.2.1 ]heptyl, 7- oxa-2-azabicyclo[2.2.1 ]heptyl, 2-thia-5-azabicyclo[2.2.1 ]heptyl,7-azabicyclo[2.2.1]heptyl, 2,6-diazatricyclo[3.3.1 .13,7]decyl, 2-azatricyclo[3.3.1 .13,7]decyl, 2,4,9- triazatricyclo[3.3.1.13,7]decyl, 8-azabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl, 2- azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1 ]octyl, 8-azabicyclo[3.2.1]octyl, octahydro-1 H- pyrrolo[3,2-6]pyridyl group. This term specifically excludes bicyclic heterocycloalkyl moieties where the rings are joined at a single atom per ring (spiro), as exemplified by the bonding arrangement in a 1-oxa-2-azaspiro[4.5]dec-2-en-3-yl group. Illustrative examples
of heterocycloalkyls include, but are not limited to, azetidinyl, pyrrolidyl (or pyrrolidinyl), piperidinyl, piperazinyl, morpholinyl, tetrahydro-2H-1 ,4-thiazinyl, tetrahydrofuryl (or tetrahydrofuranyl), dihydrofuryl, oxazolinyl, thiazolinyl, pyrazolinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3-dioxolanyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3-oxathiolanyl, 1 ,3-oxathianyl, 1 ,3-dithianyl, azabicylo[3.2.1]octyl, azabicylo[3.3.1]nonyl, azabicylo[4.3.0]nonyl, oxabicylo[2.2.1 ]heptyl and 1 ,5,9-triazacyclododecyl.
Generally, in the compounds of this invention, heterocycloalkyl groups are
5-membered and/or 6-membered heterocycloalkyl groups, such as pyrrolidyl (or pyrrolidinyl), tetrahydrofuryl (or tetrahydrofuranyl), dihydrofuryl, tetrahydrothienyl, oxazolinyl, thiazolinyl, pyrazolinyl, piperidyl (or piperidinyl), piperazinyl, morpholinyl, tetrahydropyranyl, dihydropyranyl, 1 ,3-dioxanyl, tetrahydro-2H-1 ,4-thiazinyl, 1 ,4-dioxanyl, 1 ,3-oxathianyl, and 1 ,3-dithianyl.
"Heteroaryl" represents a group or moiety comprising an aromatic, monocyclic, bicyclic or tricyclic radical, containing 5 to 14 (generally, 5-6, 9-1 1 or 13-14) ring atoms, including 1 to 4 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. The bicyclic and tricyclic heteroaryl groups or moieties may contain an aromatic carbocyclic ring moiety (e.g., a phenyl) fused to a heterocycloalkyl ring moiety, or an aromatic heterocyclic ring moiety (e.g., a pyridyl or quinolyl ring moiety) fused to a cycloalkyl/cycloalkenyl ring moiety. This term is also intended to encompass heterocyclic groups containing nitrogen and/or sulfur ring atoms where the nitrogen or sulfur heteroatoms are optionally oxidized. Illustrative examples of heteroaryls include, but are not limited to, thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl (or furanyl), isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyridyl (or pyridinyl), pyridyl-N-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrazinyl, triazolyl, tetrazolyl, benzo[b]thienyl, isobenzofuryl, 2,3-dihydrobenzofuryl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl,
benzothiazolyl, benzimidazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, isoindolinyl, indolinyl, cinnolinyl, pteridinyl, carbazolyl, acridinyl, and isothiazolyl.
Some of the heteroaryl groups present in the compounds of this invention are 5-6 membered monocyclic heteroaryl groups. Selected 5-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms. Selected 6-membered heteroaryl groups contain 1 , 2, 3 or 4 nitrogen ring heteroatoms. Selected 5- or 6-membered heteroaryl groups include thienyl, pyrrolyl, imidazolyl, pyrazolyl, furyl, isothiazolyl, furazanyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, triazolyl, and tetrazolyl or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and thiadiazolyl.
Some of the heteroaryl groups present in the compounds of this invention are 9-10 membered bicyclic heteroaryl groups. Selected 9-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2 or 3 additional nitrogen ring atoms. Selected 10-membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, 3 or 4 additional nitrogen ring atoms. Selected 9-10 membered heteroaryl groups include benzo[b]thienyl, isobenzofuryl, 2,3-dihydrobenzofuryl, chromenyl, chromanyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthridinyl, quinzolinyl,
benzothiazolyl, benzimidazolyl, tetrahydroquinolinyl, cinnolinyl, pteridinyl. Selected 13-14 membered heteroaryl groups contain one nitrogen, oxygen or sulfur ring heteroatom, and optionally contain 1 , 2, 3 or 4 additional nitrogen ring atoms. A representavtive
13-membered heteroaryl group is carbazolyl. A representavtive 14-membered heteroaryl group is acridinyl.
In addition, the terms alkyl, aryl, cycloalkyl, heteroaryl, etc. may be used to define a divalent substituent, such as a group bonded to two other groups. In this instance, such terms are intended to encompass divalent moieties. For example, "pentyl" may be used to represent a pentylenyl diradical -wherein the pentyl moiety is any one of a divalent straight (e.g. -CH2CH2CH2CH2CH2-) or branched (e.g. -CH2CH(CH3)CH2CH2-,
-CH2CH2CH(CH2CH3)-, -CH2CH2C(CH3)2-) chain 5-carbon radical.
The terms "halogen" and "halo" represent chloro, fluoro, bromo or iodo
substituents. "Hydroxy" or "hydroxyl" is intended to mean the radical -OH. The term "oxo" is intended to mean a keto diradical (=0), such as present on a pyrrolidin-2-one ring.
The compounds of the invention are only those which are contemplated to be "chemically stable" as will be appreciated by those skilled in the art.
In one embodiment of this invention, Ar is an optionally substituted aryl, 5-6 or 9-14 membered heteroaryl group, optionally substituted by 1 -2 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, (Ci-C6)alkyl, aryl, heteroaryl, halo(CrC6)alkyl, (d-C6)alkoxy, halo(CrC6)alkoxy, aryloxy (Ci-C6)alkylthio-, halo(CrC6)alkylthio-, hydroxy(CrC6)alkyl-, amino, (Ci-C6)alkylamino-, ((Ci-C6)alkyl)((Ci-C6)alkyl)amino- heterocycloalkyl, -S02NH2, -S02NH(Ci-C6)alkyl, -S02N((Ci-C6)alkyl)((Ci-C6)alkyl), -CO(C C6)alkyl, -CONH2, -CONH(Ci-C6)alkyl, and -CON((CrC6)alkyl)((Ci-C6)alkyl).
In another embodiment of this invention, Ar is an optionally substituted phenyl, pyridyl, furyl, indolyl, pyrrolyl, imidazolyl, naphthyl, quinolyl, benzimidazolyl,
benzothiofuranyl, fluorenyl, acridinyl and carbazolyl.
In another embodiment of this invention, Ar is an optionally substituted phenyl optionally substituted by a substituent selected from the group consisting of halo, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, and halo(C1-C6)alkoxy. In the specific embodiments of this invention, Ar is an unsubstituted phenyl.
In specific embodiments X is -S02NH- and has the bonding arrangement
Ar-S02NH-R.
In one embodiment of this invention, R is an optionally substituted 6, 9, or 10 membered aryl group, an optionally substituted 5, 6, 9 or 10 membered heteroaryl group, an optionally substituted 6, 9 or 10 membered aryl(Ci-C4)alkyl- group, an optionally substituted 5, 6, 9 or 10 membered heteroaryl(Ci-C4)alkyl- group, an optionally substituted 6, 9 or 10 membered aryl(C2-C4)alkenyl- group, or an optionally substituted 5, 6, 9 or 10 membered heteroaryl(C2-C4)alkenyl- group,
wherein any of said aryl or heteroaryl, (that is the aryl or heteroaryl group or the aryl or heteroaryl moiety of the aryl(Ci-C4)alkyl-, heteroaryl(Ci-C4)alkyl-,
aryl(C2-C4)alkenyl- or heteroaryl(C2-C4)alkenyl- group) is optionally substituted by 1-2 substituents each independently selected from the group consisting of halo, hydroxy, (Ci-C4)alkyl, halo(CrC4)alkyl, (d-C4)alkoxy, phenoxy-, halo(Ci-C4)alkoxy,
hydroxy(C1-C4)alkyl-, amino, (C1-C4)alkylamino-, ((C1-C4)alkyl)((C1-C4)alkyl)amino-, amino-(C1-C4)alkyl-, (C1-C4)alkylamino(C1-C4)alkyl-,
((Ci-C4)alkyl)((Ci-C4)alkyl)amino(Ci-C4)alkyl- -S02NH2, -S02NH(d-C4)alkyl,
-S02N((Ci-C4)alkyl)((Ci-C4)alkyl), -CONH2, -CONH(C C4)alkyl,
-CON((Ci-C4)alkyl)((Ci-C4)alkyl), -CO(C C4)alkyl, phenyl, and 5-6 membered
heterocycloalkyl,
and wherein the alkyl or alkylene moiety of said aryl(Ci-C4)alkyl-,
heteroaryl(Ci-C4)alkyl-, aryl(C2-C4)alkenyl-, or heteroaryl(C2-C4)alkenyl-, is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen, hydroxyl, (CrC4)alkoxy, phenyl, (Ci-C4)alkylCO-, and oxo.
In one embodiment of this invention, R is an optionally substituted phenyl, naphthyl, imidazolyl, pyridyl, furanyl, indenyl, dihydroindenyl, quinolyl, benzimidazolyl, or indolyl. In specific embodiments, R is optionally substituted by 1 , 2 or 3 independently selected R1 substituents. In a more specific embodiment, R is phenyl group, substituted by 0, 1 or 2 independently selected R1 substituents. In one emboidment each R1 substituent is independently selected from the group consisting of fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, nitro, -S02NH2, and phenyl.
In one embodiment, R is a substituted phenyl group selected from the group consisting of: 4-(fluoro)phenyl, 4-(chloro)phenyl, 4-(bromo)phenyl, 4-(iodo)phenyl, 4-(methyl) phenyl, 4-(ethyl)phenyl, 4-(isopropyl)phenyl, 4-(t-butyl)phenyl, 4-(cyano)phenyl, 4-(trifluoromethyl)phenyl, 4-(hydroxy)phenyl, 4-(methoxy)phenyl, 4-(ethoxy)phenyl, 4-(isopropoxy)phenyl, 4-(trifluoromethoxy)phenyl, 4-(difluoromethoxy)phenyl,
4-(phenoxy)phenyl, 4-(methylthio)phenyl, 4-(trifluoromethylthio)phenyl,
4-(hydroxymethyl)phenyl, 4-(amino)phenyl, 4-(dimethylamino)phenyl,
4-(diethylamino)phenyl, 4-(morpholino)phenyl; 4-(amido)phenyl, 4-(acetamido)phenyl, 4-(acetyl)phenyl, 4-(nitro)phenyl, 4-(sulfonamido)phenyl, and 4-(phenyl)phenyl.
In another embodiment, R is a substituted phenyl group selected from the group consisting of: 3,4-di(methoxy)phenyl, 3,4-di(hydroxy)phenyl, 3,4-di(methyl)phenyl, 3,4-di(fluoro)phenyl, 3-(chloro), 4-(fluoro)phenyl, 2,4-di(chloro)phenyl, 2,4-di(fluoro)phenyl,
2- (hydroxymethyl)phenyl, 3-(hydroxymethyl)phenyl, 3-(cyano)phenyl,
3- (trifluoromethylthio)phenyl, 2-(chloro)phenyl, 2-(trifluoromethyl)phenyl,
2-(hydroxymethyl)phenyl, 3,4,5-tri(methoxy)phenyl, 3,4,5-tri(chloro)phenyl,
2-(fluoro)phenyl, 3-(fluoro)phenyl, 2,6-di(fluoro)phenyl, 2,6-di(methyl)phenyl,
2,6-di(isopropyl)phenyl, 2,6-di(fluoro)phenyl, 2-(fluoro), 4-(bromo)phenyl,
2-(trifluoromethyl), 4-(fluoro)phenyl, 2-(trifluoromethyl), 4-(chloro)phenyl, 2-(methoxy),
4- (trifluoromethyl)phenyl, 2-(chloro), 4-(bromo)phenyl, 2-(fluoro), 4-(bromo)phenyl, 2-(fluoro), 4-(bromo)phenyl, 3,5-di(fluoro)phenyl, and 3,5-di(trifluoromethyl)phenyl.
In one embodiment, R2 is hydrogen, (C1-C6)alkyl or aryl. In another embodiment, R2 is H or (CrC4)alkyl. In another embodiment R2 is H, methyl or ethyl.
Specifically, the invention is directed to a compound according to Formula (l-a):
wherein n is 0, 1 , 2, or 3, specifically n is 0, 1 , or 2, and more specifically, n is 0 or1 ; and each R1 is independently selected from the group consisting of fluoro, chloro, bromo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino, dimethylamino, diethylamino, morpholino, -CONH2, -COCH3, nitro, -S02NH2, and phenyl, or a salt thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof. In a specific embodiment of the compound of Formula (l-a) n is 0.
As used herein, the terms "compound(s) of the invention" or "compound(s) of this invention" mean a compound of Formula (I), as defined above, in any form, i.e., any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly a
pharmaceutically acceptable salt thereof) and any physical form thereof (e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
As used herein, the term "optionally substituted" means unsubstituted groups or rings (e.g., cycloalkyl, heterocycle, and heteroaryl rings) and groups or rings substituted with one or more specified substituents.
The compounds according to Formula I may contain one or more asymmetric center (also referred to as a chiral center) and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. Chiral centers, such as chiral carbon atoms, may also be present in a substituent such as an alkyl group. Where the stereochemistry of a chiral center present in Formula I, or in any chemical structure illustrated herein, is not specified the structure is intended to encompass all individual stereoisomers and all mixtures thereof. Thus, compounds according to Formula I containing one or more chiral centers may be used as racemic mixtures, scalemic mixtures, or as diaseteromerically or enantiomerically pure materials.
Individual stereoisomers of a compound according to Formula I which contain one or more asymmetric center may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1 ) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer- specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent. The skilled artisan will appreciate that where the desired stereoisomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired form. Alternatively, specific stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
When a disclosed compound or its salt is named or depicted by structure, it is to be understood that the compound or salt, including solvates (particularly, hydrates) thereof, may exist in crystalline forms, non-crystalline forms or a mixture thereof. The compound or salt, or solvates (particularly, hydrates) thereof, may also exhibit
polymorphism (i.e. the capacity to occur in different crystalline forms). These different
crystalline forms are typically known as "polymorphs." It is to be understood that when named or depicted by structure, the disclosed compound, or solvates (particularly, hydrates) thereof, also include all polymorphs thereof. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification. One of ordinary skill in the art will appreciate that different polymorphs may be produced, for example, by changing or adjusting the conditions used in crystallizing/recrystallizing the compound.
Because of their potential use in medicine, the salts of the compounds of
Formula I are preferably pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse,
J.Pharm.Sci (1977) 66, pp 1 -19. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention.
Typically, a salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
When a compound of the invention is a base (contain a basic moiety), a desired salt form may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, and the like, or with a pyranosidyl acid, such as glucuronic acid or galacturonic acid, or with an alpha-hydroxy acid, such as citric acid or tartaric acid, or with an amino acid, such as aspartic acid or glutamic acid, or with an aromatic acid, such as benzoic acid or cinnamic acid, or with a sulfonic acid, such as p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid or the like.
Suitable addition salts are formed from acids which form non-toxic salts and examples include acetate, p-aminobenzoate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bismethylenesalicylate, bisulfate, bitartrate, borate, calcium edetate, camsylate, carbonate, clavulanate, citrate, cyclohexylsulfamate, edetate, edisylate, estolate, esylate, ethanedisulfonate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, dihydrochloride, hydrofumarate, hydrogen
phosphate, hydroiodide, hydromaleate, hydrosuccinate, hydroxynaphthoate, isethionate, itaconate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, oxaloacetate, pamoate (embonate), palmate, palmitate, pantothenate, phosphate/diphosphate, pyruvate, polygalacturonate, propionate, saccharate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate, triethiodide, trifluoroacetate and valerate.
Other exemplary acid addition salts include pyrosulfate, sulfite, bisulfite, decanoate, caprylate, acrylate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, suberate, sebacate, butyne-1 ,4-dioate, hexyne-1 ,6-dioate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, phenylacetate, phenylpropionate, phenylbutrate, lactate, γ-hydroxybutyrate, mandelate, and sulfonates, such as xylenesulfonate, propanesulfonate, naphthalene-1 -sulfonate and naphthalene-2-sulfonate.
If an inventive basic compound is isolated as a salt, the corresponding free base form of that compound may be prepared by any suitable method known to the art, including treatment of the salt with an inorganic or organic base, suitably an inorganic or organic base having a higher pKa than the free base form of the compound.
When a compound of the invention is an acid (contains an acidic moiety), a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal or alkaline earth metal hydroxide, or the like.
Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as N-methyl-D-glucamine, diethylamine, isopropylamine, trimethylamine, ethylene diamine, dicyclohexylamine, ethanolamine, piperidine, morpholine, and piperazine, as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
Certain of the compounds of this invention may form salts with one or more equivalents of an acid (if the compound contains a basic moiety) or a base (if the compound contains an acidic moiety). The present invention includes within its scope all possible stoichiometric and non-stoichiometric salt forms.
Compounds of the invention having both a basic and acidic moiety may be in the form of zwitterions, acid-addition salt of the basic moiety or base salts of the acidic moiety.
This invention also provides for the conversion of one pharmaceutically acceptable salt of a compound of this invention, e.g., a hydrochloride salt, into another
pharmaceutically acceptable salt of a compound of this invention, e.g., a sulfate salt.
For solvates of the compounds of Formula I, or salts thereof that are in crystalline form, the skilled artisan will appreciate that pharmaceutically-acceptable solvates may be formed wherein solvent molecules are incorporated into the crystalline lattice during crystallization. Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice. Solvates wherein water is the solvent that is incorporated into the crystalline lattice are typically referred to as
"hydrates." Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The invention includes all such solvates.
Because the compounds of Formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions.
The compounds of this invention may be obtained by using synthetic procedures illustrated in the Schemes below or by drawing on the knowledge of a skilled organic chemist. The synthesis provided in these Schemes are applicable for producing compounds of the invention having a variety of different R1 and R2 groups employing appropriate precursors, which are suitably protected if needed, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, where needed, affords compounds of the nature generally disclosed. While the Schemes are shown with compounds only of Formula I, they are illustrative of processes that may be used to make the compounds of the invention.
Intermediates (compounds used in the preparation of the compounds of the invention) may also be present as salts. Thus, in reference to intermediates, the phrase "compound(s) of formula (number)" means a compound having that structural formula or a pharmaceutically acceptable salt thereof.
Specific compounds of this invention are the compounds of Examples 1 -2, including salts, particularly pharmaceutically acceptable salts, thereof.
Other compounds that may be prepared using the methods described herein include:
(E)-N-methyl-N-phenyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(benzo[d][1 ,3]dioxol-5-ylmethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-3,4-dimethoxy-N-(4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)phenyl)benzenesulfonamide,
(E)-N-(4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)phenyl)-[1 , 1 '-biphenyl]-4- sulfonamide,
(E)-N-(4-chlorophenyl)-4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)phenyl)benzenesulfonamide,
(E)-N-(naphthalen-2-yl)-4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-phenyl-4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-phenethyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(p-tolyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-4-methyl-N-(3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)phenyl)benzenesulfonamide,
(E)-N-(3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)phenyl)-[1 , 1 '-biphenyl]-4- sulfonamide,
(E)-3,4-dimethoxy-N-(3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)phenyl)benzenesulfonamide,
(E)-2-phenyl-N-(3-((E)-2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)phenyl)ethenesulfonamide,
(E)-N-(naphthalen-2-yl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(naphthalen-1 -yl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-methoxyphenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(pyridin-3-ylmethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(naphthalen-1 -ylmethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(furan-2-ylmethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-methoxy-5-(trifluoromethyl)phenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)vinyl)benzenesulfonamide,
(E)-N-(3-fluorophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-fluorophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2,4-difluorophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(9-ethyl-9H-carbazol-3-yl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(4-(difluoromethoxy)phenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(3,4-dimethoxyphenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide
(E)-N-(3,4-dimethoxyphenethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-N-(3,4,5- trimethoxybenzyl)benzenesulfonamide,
(E)-N-(4-(trifluoromethoxy)phenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(1 ,2-diphenylethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-benzhydryl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide
(E)-N-(2,3-dihydro-1 H-inden-2-yl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(3-bromophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-([1 , 1 '-biphenyl]-4-yl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-([1 , 1 '-biphenyl]-2-yl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(3-methoxyphenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-phenethyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-benzyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(4-chlorophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(4-bromophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(p-tolyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(4-methoxyphenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-([1 , 1 '-biphenyl]-4-yl)-4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-1 -phenyl-N-(4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)phenyl)methanesulfonamide,
(E)-N-(4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)phenyl)benzenesulfonamide,
(E)-N-(3,4-dimethoxyphenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-fluorophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(3-fluorophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-methoxy-5-(trifluoromethyl)phenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)vinyl)benzenesulfonamide,
(E)-N-(4-cyanophenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-N-(4- (trifluoromethyl)phenyl)benzenesulfonamide,
(E)-N-(4-sulfamoylphenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(4-(tert-butyl)phenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(4-hydroxyphenyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N,N-diphenyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-isobutyl-N-phenyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-butyl-N-phenyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(quinolin-4-yl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N,N-dibenzyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-butyl-N-(2-phenylpropyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-(1 H-indol-3-yl)ethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-(1 H-benzo[d]imidazol-2-yl)ethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl)vinyl)benzenesulfonamide,
(E)-N-(2-(pyridin-2-yl)ethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-(1 H-imidazol-4-yl)ethyl)-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
N-cinnamyl-3-((E)-2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide,
(E)-N-(2-(1 H-indol-2-yl)ethyl)-N-methyl-4-((3-(2-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)vinyl)-1 H-pyrrol-1-yl)sulfonyl)aniline,
(E)-N-(2-(1 H-indol-2-yl)ethyl)-N-methyl-4-((3-(2-(5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl)vinyl)-1 H-pyrrol-1-yl)sulfonyl)aniline,
(E)-3-(2-(1 -((3-(1 H-pyrazol-4-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-l ,2,4-oxadiazole,
(E)-3-(2-(1 -((3-(1 H-pyrazol-4-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-3-(2-(1 -((3-(pyridin-3-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-3-(2-(1 -((3-(pyridin-4-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5-
(trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-3-(2-(1 -((3-(pyridin-4-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-2-((2-(1 H-indol-2-yl)ethyl)(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)-1 H-pyrrol-1 -yl)sulfonyl)benzyl)amino)ethanol,
(E)-4-(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H-pyrrol-1 - yl)sulfonyl)benzyl)morpholine,
(E)-3-(2-(1 -((5-(pyridin-2-yl)thiophen-2-yl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-3-(2-(1 -((4-(1 H-pyrazol-1 -yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-l ,2,4-oxadiazole,
(E)-3-(2-(1 -((5-(pyridin-2-yl)thiophen-2-yl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-3-(2-(1 -([1 ,1 '-biphenyl]-3-ylsulfonyl)-1 H-pyrrol-3-yl)vinyl)-5-(trifluoromethyl)- 1 ,2,4-oxadiazole,
(E)-3-(2-(1 -((4-(1 H-pyrazol-4-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5-
(trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-3-(2-(1 -((4-(pyridin-3-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-3-(2-(1 -((4-(pyridin-4-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-l ,2,4-oxadiazole
(E)-3-(2-(1 -((4-(1 H-pyrazol-4-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-3-(2-(1 -((4-(pyridin-4-yl)phenyl)sulfonyl)-1 H-pyrrol-3-yl)vinyl)-5- (trifluoromethyl)-1 ,2,4-oxadiazole,
(E)-(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H-pyrrol-1 - yl)sulfonyl)phenyl)methanamine
(E)-1 -(pyridin-4-yl)-N-(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H- pyrrol-1-yl)sulfonyl)benzyl)methanamine,
(E)-N-((1 H-indol-5-yl)methyl)-1-(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)-1 H-pyrrol-1 -yl)sulfonyl)phenyl)methanamine,
(E)-2-methyl-N-(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H-pyrrol-1 - yl)sulfonyl)benzyl)propan-1 -amine,
(E)-N-benzyl-1 -(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H-pyrrol-1 - yl)sulfonyl)phenyl)methanamine,
(E)-N-((1 H-indol-3-yl)methyl)-1-(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)-1 H-pyrrol-1 -yl)sulfonyl)phenyl)methanamine,
(E)-1 -(pyridin-3-yl)-N-(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H- pyrrol-1-yl)sulfonyl)benzyl)methanamine,
(E)-N,N-dimethyl-1 -(4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H- pyrrol-1-yl)sulfonyl)phenyl)methanamine,
(E)-N,N-dimethyl-4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H-pyrrol- 1-yl)sulfonyl)aniline,
(E)-3-(2-(1 -([1 ,1 '-biphenyl]-4-ylsulfonyl)-1 H-pyrrol-3-yl)vinyl)-5-(trifluoromethyl)- 1 ,2,4-oxadiazole,
(E)-3-(2-(1 -(benzylsulfonyl)-l H-pyrrol-3-yl)vinyl)-5-(trifluoromethyl)-1 ,2,4- oxadiazole,
(E)-3-(2-(1 -tosyl-1 H-pyrrol-3-yl)vinyl)-5-(trifluoromethyl)-1 ,2,4-oxadiazole, (E)-N,N-dimethyl-4-((3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl)vinyl)-1 H-pyrrol- 1-yl)sulfonyl)aniline,
(E)-3-(2-(1 -([1 ,1 '-biphenyl]-4-ylsulfonyl)-1 H-pyrrol-3-yl)vinyl)-5-(trifluoromethyl)- 1 ,2,4-oxadiazole,
(E)-3-(2-(1 -(benzylsulfonyl)-l H-pyrrol-3-yl)vinyl)-5-(trifluoromethyl)-1 ,2,4- oxadiazole, and
(E)-3-(2-(1 -tosyl-1 H-pyrrol-3-yl)vinyl)-5-(trifluoromethyl)-1 ,2,4-oxadiazole, and salts, particularly pharmaceutically acceptable salts, thereof.
Compound names were generated using the software naming program
ChemDraw 1 1.0 available from CambridgeSoft Corporation., 100 CambridgePark Drive,
Cambridge, MA 02140, USA (http://www.cambridgesoft.com).
The compounds of Formula I can be prepared according to the methods outlined below.
Scheme
A halo-(hetero)aryl sulfonyl chloride may be treated with an amine (NH2R2) to provide a halo-substituted (hetero)arylsulfonamide. This sulfonamide may be treated with cyano-ethylene, palladium on carbon, tri-otolylphospine, potassium acetate and tetrabutylammonium chloride to provide the homologated (hetero)arylsulfonamide, which may be treated with hydroxylamine, followed by trifluoroacetic anhydrideto provide the target oxadiazolyl compounds.
The invention also includes various deuterated forms of the compounds of Formula I. Each available hydrogen atom attached to a carbon atom may be
independently replaced with a deuterium atom. A person of ordinary skill in the art will know how to synthesize deuterated forms of the compounds of Formula I. For example, deuterated alkyl groups (e.g., /V-(deutero-methyl) amines) may be prepared by
conventional techniques (see for example: methyl-c/3-amine available from Aldrich
Chemical Co., Milwaukee, Wl, Cat. No.489, 689-2). Employing such compounds will allow for the preparation of compounds of Formula I in which various hydrogen atoms of the N- methyl groups are replaced with a deuterium atom.
The present invention is directed to a method of inhibiting an HDAC which comprises contacting the acetylase with a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. More specifically, this invention is directed to a method of inhibiting HDAC comprising contacting a cell with an effective amount of a compound of Formula (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof. This invention is also directed to a method of treatment of an HDAC-mediated disease or disorder comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof. As used herein, "patient" refers to a mammal, specifically, a human. A therapeutically "effective amount" is intended to mean that amount of a compound that, when administered to a patient in need of such treatment, is sufficient to effect treatment, as defined herein.
Thus, e.g., a therapeutically effective amount of a compound of Formula I, or a
pharmaceutically acceptable salt thereof, is a quantity of an inventive agent that, when administered to a human in need thereof, is sufficient to inhibit the activity of HDAC such that a disease condition which is mediated by that activity is reduced, alleviated or prevented. The amount of a given compound that will correspond to such an amount will vary depending upon factors such as the particular compound (e.g., the potency (pXC5o), efficacy (EC50), and the biological half-life of the particular compound), disease condition and its severity, the identity (e.g., age, size and weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art. Likewise, the
duration of treatment and the time period of administration (time period between dosages and the timing of the dosages, e.g., before/with/after meals) of the compound will vary according to the identity of the mammal in need of treatment (e.g., weight), the particular compound and its properties (e.g., pharmaceutical characteristics), disease or condition and its severity and the specific composition and method being used, but can
nevertheless be determined by one of skill in the art.
"Treating" or "treatment" is intended to mean at least the mitigation of a disease condition in a patient, where the disease condition is caused or mediated by HDAC. The methods of treatment for mitigation of a disease condition include the use of the compounds in this invention in any conventionally acceptable manner, for example for prevention, retardation, prophylaxis, therapy or cure of a disease.
In one embodiment, this invention is directed to a method of treating, ameliorating, or preventing an autoimmune disorder, an immunological disease, an inflammatory disorder, transplant/graft rejection (e.g., allograft), lymphopenia, or graft-versus-host disease (GvHD) in a patient, specifically in a human, comprising administering to the patient a compound of this invention, in an amount sufficient to increase the level and/or activity of a Treg cell or a population of Treg cells in the patient, thereby treating, ameliorating, or preventing the autoimmune disorder, inflammatory disorder,
transplant/graft rejection, lymphopenia, or GvHD in the patient.
Additional examples of diseases and conditions that may be treated by the compounds of this invention include but not limited to type II diabetes mellitus, coronary artery disease, alopecia, allergies and allergic reactions, and sepsis/toxic shock.
Exemplary autoimmune disorders include, but are not limited to, multiple sclerosis, juvenile idiopathic arthritis, psoriatic arthritis, hepatitis C virus-associated mixed cryoglobulinemia, polymyositis, dermatomyositis, polyglandular syndrome type II, autoimmune liver disease, Kawasaki disease, myasthenia gravis, immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX (syndrome)), type I diabetes, psoriasis, hypothyroidism, hemolytic anemia, autoimmune polyendocrinopathy- candidiasis-ectodermal dystrophy (APECED), thrombocytopenia, spondyloarthritis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, eczema, gastritis, or thyroiditis. As part of a nonlimiting list, the inflammatory disorder can be contact hypersensitivity, atopic dermatitis or Still disease.
Additional examples of autoimmune diseases include but are not limited to autoimmune diseases include osteoarthritis, systemic sclerosis, sarcoidosis, insulin dependent diabetes mellitus (IDDM, type I diabetes), reactive arthritis, scleroderma, vasculitis, Wegener's granulomatosis, Hashimoto's disease, scleroderma, oophoritis,
Lupus (SLE), Grave's disease, asthma, cryoglobulinemia, primary biliary sclerosis, pemphigus vulgaris, hemolytic anemia and pernicious anemia.
Examples of transplant/graft rejection (e.g., allograft), lymphopenia, or graft- versus-host disease (GvHD) are those arising from cell, tissue and organ transplantation procedures, such as therapeutic cell transplants such as stem cells, muscle cells such as cardiac cells, islet cells, liver cells, bone marrow transplants, skin grafts, bone grafts, lung transplants, kidney transplants, liver transplants, and heart transplants.
In another embodiment, this invention is directed to a method of treating an HDAC-mediated neurodegenerative disease or disorder which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof. This invention is also directed to a method of treatment of a neurodegenerative disease or disorder associated with deacetylases, such as, Alzheimer's disease, Parkinson's disease, neuronal intranuclear inclusion disease (NMD), and polyglutamine disorders, such as Huntington's disease and spinocerebellar ataxia (SCA), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
Other examples of diseases and conditions that may be treated by the compounds of this invention include but are not limited to cystic fibrosis, osteoporosis, obesity, epilepsy, depression, thalassemia, sickle cell anemia, amyotrophic lateral sclerosis (ALS) and hyperalgesia, cardiac disease (e.g., stroke, hypertension, atherothrombotic diseases, artherosclerosis or limitation of infarct size in acute coronary syndrome), diseases or disorders involving muscular atrophy, gentamicin-induced hearing loss, drug resistance (e.g., drug resistance in osteosarcoma and colon cancer cells), infectious diseases, and immune deficiency/immunocompromised patients. Examples of infectious diseases relate to various pathogen infections such as viral, fungal, bacterial, mycoplasm, and infections by unicellular and multicellular eukaryotic organisms. Common human pathogens include but are not limited to HIV, HSV, HPV, Hepatitis A, B and C viruses, influenza, denge, zostrella, rubella, RSV, rotavirus, gram positive, gram negative, streptococcus, tetanus, staphalococcus, tuberculosis, listeria, and malaria.
The compounds of the invention may be employed alone or in combination with standard anti-cancer regimens for neoplastic cell, e.g., tumor cell and cancer cell, treatments. Thus, in another embodiment, this invention is directed to inhibitors of HDAC and their use to stop or reduce the growth of neoplastic cells, e.g., cancer cells and tumor cells. The growth of cancer cells and/or tumor cells that are found in the following cancer types may be reduced by treatment with a compound of this invention: carcinoma (e.g.,
adenocarcinoma), heptaocellular carcinoma, sarcoma, myeloma (e.g., multiple myeloma), treating bone disease in multiple myeloma, leukemia, childhood acute lymphoblastic leukemia and lymphoma (e.g., cutaneous cell lymphoma), and mixed types of cancers, such as adenosquamous carcinoma, mixed mesodermal tumor, carcinosarcoma, and teratocarcinoma. In one aspect of the invention, breast or prostate cancers or tumors are treated using the HDAC inhibitors of this invention. Other cancers that may be treated using the compounds of this invention include, but are not limited to, bladder cancer, breast cancer, prostate cancer, stomach cancer, lung cancer, colon cancer, rectal cancer, colorectal cancer, liver cancer, endometrial cancer, pancreatic cancer, cervical cancer, ovarian cancer; head and neck cancer, and melanoma.
The present invention is further directed to a method of treating a B-cell lymphoma, particularly a B-cell lymphoma associated with deacetylases, which comprises administering to a patient in need thereof, a compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof. Examples of B-cell lymphomas associated with deacetylases that may be treated using the method of this invention include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and
Waldenstrom Macroglobulinemia (lymphoplasmacytic lymphoma). More specifically, this invention is directed to a method of treatment of Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, and Waldenstrom Macroglobulinemia (lymphoplasmacytic lymphoma), comprising administering a therapeutically effective amount of the compound of Formula I or a salt thereof, particularly a pharmaceutically acceptable salt thereof, to a patient, specifically a human, in need thereof.
The compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
Systemic administration includes oral administration, parenteral administration, transdermal administration, rectal administration, and administration by inhalation.
Parenteral administration refers to routes of administration other than enteral,
transdermal, or by inhalation, and is typically by injection or infusion. Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion. Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages. Topical administration includes application to the skin.
The compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
Treatment of HDAC-mediated disease conditions may be achieved using the compounds of this invention as a monotherapy, or in dual or multiple combination therapy, such as in combination with other agents, for example, in combination with one or more of the following agents: DNA methyltransferase inhibitors, acetyl transferase enhancers, proteasome or HSP90 inhibitors, and one or more immunosuppressants that do not activate the T suppressor cells including but are not limited to corticosteroids, rapamycin, Azathioprine, Mycophenolate, Cyclosporine, Mercaptopurine (6-MP), basiliximab, daclizumab, sirolimus, tacrolimus, Muromonab-CD3, cyclophosphamide, and
methotrexate, which are administered in effective amounts as is known in the art.
The compounds of the invention will normally, but not necessarily, be formulated into a pharmaceutical composition prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and a pharmaceutically-acceptable excipient.
The pharmaceutical compositions of the invention may be prepared and packaged in bulk form wherein an effective amount of a compound of the invention can be extracted and then given to the patient such as with powders, syrups, and solutions for injection. Alternatively, the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form. For oral application, for example, one or more tablets or capsules may be administered. A dose of the pharmaceutical composition contains at least a therapeutically effective amount of a compound of this invention (i.e., a compound of Formula I or a salt, particularly a pharmaceutically acceptable salt, thereof). When
prepared in unit dosage form, the pharmaceutical compositions may contain from 1 mg to 1000 mg of a compound of this invention.
The pharmaceutical compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
As used herein, "pharmaceutically-acceptable excipient" means a material, composition or vehicle involved in giving form or consistency to the composition. Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically-acceptable are avoided. In addition, each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
The compounds of the invention and the pharmaceutically-acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration. Conventional dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition. For example, certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically- acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body. Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents. The skilled artisan will appreciate that certain pharmaceutically-acceptable excipients may serve more than one function and may serve alternative functions depending on how much of the excipient is present in the formulation and what other ingredients are present in the formulation.
Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention. In addition, there are a number of resources that are available to the skilled artisan which describe pharmaceutically-acceptable excipients and may be useful in selecting suitable pharmaceutically-acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
The pharmaceutical compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing
Company).
In one aspect, the invention is directed to a solid oral dosage form such as a tablet or capsule comprising an effective amount of a compound of the invention and a diluent or filler. Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate. The oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g. corn starch, potato starch, and pre-gelatinized starch), gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g. microcrystalline cellulose). The oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose. The oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
EXAMPLES
The following examples illustrate the invention. These examples are not intended to limit the scope of the present invention, but rather to provide guidance to the skilled artisan to prepare and use the compounds, compositions, and methods of the present invention. While particular embodiments of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without departing from the spirit and scope of the invention.
In the following experimental descriptions, the following abbreviations may be used:
NH4CI ammonium chloride
NiCI2-6H20 nickel (II) chloride hexahydrate
NMP W-methyl-2-pyrrolidone
Ph phenyl
rt room temperature
satd saturated
sex strong cation exchange
SPE solid phase extraction
TFA trifluoroacetic acid
THF tetrahydrofuran
fR retention time
EXAMPLE 1
3-Bromo-W-phenylbenzenesulfonamide: 3-Bromobenzene-1-sulfonyl chloride (1 .02 g, 4.0 mmol) was added to a stirring solution of aniline (0.365 mL, 4.0 mmol) and Et3N (0.84 mL, 6.0 mmol) in DCM (25 mL). The reaction mixture was allowed to stir 3 h. The reaction mixture was concentrated under reduced pressure and purified by silica gel
chromatography (0% - 100% DCM in hexanes elution) to yield the title compound as a clear, viscous oil (1 .15 g, 92%), which was progressed without further purification. 1H NMR (400 MHz, CHLOROFORM-d) δ 7.68 (t, J = 7.05 Hz, 1 H), 7.24 - 7.40 (m, 2H), 7.19 (t, J = 7.93 Hz, 2H), 7.09 (d, J = 7.83 Hz, 1 H), 6.79 (t, J = 7.34 Hz, 1 H), 6.72 (d, J = 7.63 Hz, 2H), 6.66 (br. s., 1 H). LCMS: fR = 0.87 min, 78%. MS m/z = 309 (M - H)-.
(E)-3-(2-Cyanovinyl)-A -phenylbenzenesulfonamide: /V,/V-Dimethylacetamide (DMA) (3 mL) and acrylonitrile (0.076 mL, 1.153 mmol) were added to a 5 ml microwave vial containing 3-bromo-/V-phenylbenzenesulfonamide (240 mg, 0.769 mmol), 10 wt% palladium on carbon (40.9 mg, 0.038 mmol), tri-o-tolylphosphine (23 mg, 0.077 mmol), potassium acetate (91 mg, 0.923 mmol), and tetrabutylammonium chloride (214 mg,
0.769 mmol). The resulting mixture was heated at 150 °C for 30 min with microwave irradiation. The reaction mixture was filtered through Celite, diluted with EtOAc (50 ml), washed with water (2 x 20 ml) and brine (20 ml), concentrated under reduced pressure, and purified by silica gel chromatography (0% - 40% EtOAc in hexanes elution) to yield the title compound as a viscous brown oil (190 mg, 87%). LCMS: fR = 0.78 min, 93%. MS m/z = 285 (M+H)+.
(E)-W-Phenyl-3-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide: Hydroxylamine (0.20 mL, 3.3 mmol) was added to a stirring solution of (£)-3-(2-cyanovinyl)-/V-phenylbenzenesulfonamide (190 mg, 0.67 mmol) in ethanol (5 mL). The resulting solution was heated at 60 °C for 2 h. The volatiles were removed under reduced pressure, and the residue was dissolved in THF (5 mL). Et3N (0.14 mL, 1.002 mmol) was then added, followed by drop-wise addition of TFAA (0.1 1 mL, 0.802 mmol). The reaction mixture was heated at 60 °C overnight. The reaction mixture was diluted with EtOAc (80 ml), washed with water (2 x 20 ml) and brine (20 ml), concentrated under reduced pressure, and purified by silica gel chromatography (0% - 100% DCM in hexanes elution) to yield the title compound as a yellow solid (47 mg, 18%). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.01 (s, 1 H), 7.69 - 7.92 (m, 3 H), 7.51 - 7.60 (m, 1 H), 7.28 - 7.36 (m, 2 H), 7.1 1 - 7.24 (m, 3 H), 6.90 (s, 1 H). LCMS: fR = 0.98 min, 92%. MS m/z = 396 (M+H)+.
4-Bromo-A -(m-tolyl)benzenesulfonamide: DCM (92 ml), 4-bromobenzene-1-sulfonyl chloride (2.385 g, 9.33 mmol), and m-toluidine (1.01 1 ml, 9.33 mmol) were added to a round bottom flask. The reaction was stirred for 2 hours and the solvent was removed under reduced pressure to give the title compound as a solid, which was used crude without further purification. LCMS: fR = 0.88 min, 100%. MS m/z = 324 (M - H)\
(E)-4-(2-Cyanovinyl)-A -(m-tolyl)benzenesulfonamide: /V,/V-Dimethylacetamide (DMA) (3497 μΙ), palladium (5.75 mg, 0.054 mmol), tri-o-tolylphosphine (32.9 mg, 0.108 mmol), potassium acetate (127 mg, 1.297 mmol), acrylonitrile (107 μΙ, 1.621 mmol), 4-bromo-/V- (m-tolyl)benzenesulfonamide (353 mg, 1.081 mmol), and tetrabutylammonium chloride (300 mg, 1.081 mmol) were added to a microwave vial. The reaction was heated to 150 °C degrees for 30 min. The reaction was filtered and the solvent was removed under reduced pressure to give the title compound, which was used without further purification. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.78 - 7.88 (m, 2 H), 7.64 (d, J = 8.4 Hz, 2 H), 7.08 - 7.21 (m, 2 H), 6.80 - 7.04 (m, 3 H), 6.42 (s, 1 H), 2.30 (s, 3 H). LCMS: fR = 0.80 min, 44%. MS m/z = 296 (M - H)-.
(E)-W-(m-Tolyl)-4-(2-(5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl)vinyl)benzenesulfonamide): (£)-4-(2-Cyanovinyl)-/V-(m-tolyl)benzenesulfonamide (0.081 g, 0.27 mmol), ethanol (1.222 ml), /'-Pr2NEt (0.141 ml, 0.810 mmol), and hydroxylamine hydrochloride (0.041 g, 0.594 mmol) were added to a round bottom flask. The reaction was refluxed for 4 h, and the solvent was removed under reduced pressure. THF (1 .222 ml), DMAP (0.033 g, 0.270 mmol), and TFAA (0.1 14 ml, 0.810 mmol) were added to the crude material, and the resulting reaction was stirred at rt for 3 hours. The reaction was concentrated under reduced pressure, diluted with DCM (50 mL), quenched with aqueous NH4CI, washed with brine, dried with MgS04, filtered, and concentrated under reduced pressure to the title compound (8 mg, 7.24%) as a white solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.78 - 7.88 (m, 2 H), 7.64 (d, J = 8.4 Hz, 2 H), 7.08 - 7.21 (m, 2 H), 6.80 - 7.04 (m, 3 H), 6.42 (s, 1 H), 2.30 (s, 3 H). LCMS: fR = 0.97 min, 97%. MS m/z = 408 (M-H)\
Pharmaceutical Compositions
Example A
Tablets are prepared using conventional methods and are formulated as follows:
Inqredient Amount per tablet
Compound 1 5mg
Microcrystalline cellulose 100mg
Lactose 100mg
Sodium starch glycollate 30mg
Maqnesium stearate 2mq
Total 237mg
Example B
Capsules are prepared using conventional methods and are formulated as follows
Inqredient Amount per tablet
Compound 15mg
Dried starch 178mg
Maqnesium stearate 2mq
Total 195mg
Histone Deacetylase 9 (HDAC9) Inhibition Assay:
Novel histone deacetylase 9 (HDAC9) inhibitors were characterized in an in vitro biochemical functional assay. The assay measures the increased fluorescent signal due to deacetylation, by HDAC9, of a fluorogenic substrate. The commercial available substrate is Class lla HDAC-specific and contains an acetylated lysine residue and would releases the fluorescent signal upon trypsin cleavage after deacetylation.
Specifically, test compounds diluted to various concentrations in 100% DMSO are first dispensed into 384-well assay plates. Recombinant HDAC9 isoform 4 (purchased from BPS Bioscience) in complete assay buffer (50 mM Tris-HCI, pH 8.0, 137 mM NaCI, 2.7 mM KCI, 1 mM MgCI2, 0.05% BSA & 0.005% Tween 20) were then added to each well (5uL/well) using Multidrop Combi (Thermo Scientific), followed by 5 uL/well substrate (purchased from BPS Bioscience, 4.5 uM final). After 45 minutes incubation at room temperature, 10uL 2x developer solution (assay buffer with 40 uM Trypsin and 20 uM Trichostatin A) was added. The plates were then incubated 1 hour at room temperature before reading in fluorescent intensity mode at 450nm in an Envision (Perkin Elmer) plate
reader. Percent Inhibition of HDAC9 activity by compounds in each test wells was calculated by normalizing to fluorescent signal in control wells containing DMSO only. The plC50s value of test compounds were calculated from non-linear curve fitting, using ActivityBase5 data analysis tool (IDBS), from 1 1 point 3x dilution series starting from 100 uM final compound concentration.
For concentration/dose response experiments, normalized data were fit and plC50s determined using conventional techniques. The plC50s are averaged to determine a mean value, for a minimum of 2 experiments. As determined using the above method, the compounds of Examples 1-2 exhibited a plC50 between 5.0 and 9.0, for example, the compound of Example 2 inhibited HDAC9 in the above method with a mean plC50 > 5.5.
References:
US 20060269559, US Patent No. 7,521 ,044, WO2007084775
"Deacetylase inhibition promotes the generation and function of regulatory T cells," R.Tao, E. F. de Zoeten, E. O" zkaynak, C. Chen, L. Wang, P. M. Porrett, B. Li, L. A.
Turka, E. N. Olson, M. I. Greene, A. D. Wells, W. W. Hancock, Nature Medicine, 13 (1 1 ),
2007.
"Expression of HDAC9 by T Regulatory Cells Prevents Colitis in Mice," E. F. de
Zoeten, L. Wang, H. Sai, W. H. Dillmann, W. W. Hancock, Gastroenterology. 2009 Oct 28.
"Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of
FOXP3+ regulatory T cells," L. Wang, E. F. de Zoeten, M. I. Greene and W. W. Hancock,
Nature Review Drug Discovery. 8(12):969-81 , 2009 and references therein.
"HDAC7 targeting enhances FOXP3+ Treg function and induces long-term allograft survival," L. Wang, et al., Am. J. Transplant 9, S621 (2009).
"Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes," A. Nebbioso, F. Manzo, M. Miceli, M. Conte, L.
Manente, A. Baldi, A. De Luca, D. Rotili, S. Valente, A. Mai, A. Usiello, H. Gronemeyer, L.
Altucci, EMBO reports 10 (7) , 776-782, 2009. and references therein.
"Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender- Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor," E. van Rooij,
J. Fielitz, L. B. Sutherland, V. L. Thijssen, H. J. Crijns, M. J. Dimaio, J. Shelton, L. J. De
Windt, J. A. Hill, E.N. Olson, Circulation Research, Jan 2010.
Claims
1. A compound according to Formula I:
Ar is an optionally substituted aryl or heteroaryl group, wherein said aryl or heteroaryl is optionally substituted by 1-3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, (CrC6)alkyl, halo(CrC6)alkyl, (Ci-C6)alkoxy, aryloxy, halo(C C6)alkoxy, (d-C6)alkylthio-, halo(C C6)alkylthio-, hydroxy(CrC6)alkyl-, amino, (Ci-C6)alkylamino-, ((Ci-C6)alkyl)((Ci-C6)alkyl)amino-, -S02NH2, -S02NH(CrC6)alkyl, -S02N((Ci-C6)alkyl)((Ci-C6)alkyl), -CO(Ci-C6)alkyl, -CONH2, -CONH(Ci-C6)alkyl, -CON((Ci-C6)alkyl)((C C6)alkyl), aryl, heteroaryl, and 5-6 membered heterocycloalkyl,
wherein said optionally substituted aryl is an optionally substituted 6, 9-10 or 13-14 membered aryl, and said optionally substituted heteroaryl is an optionally substituted 5-6, 9-10 or 13-14 membered heteroaryl group and wherein said 5-6 membered
heterocycloalkyl, 5-6, 9-10 or 13-14 membered heteroaryl contains 1-4 hetereoatoms each independently selected from the group consisting of nitrogen, oxygen and sulfur;
X is -S02-, -S02NR2- or -NR2S02-;
R is an optionally substituted aryl, heteroaryl, (C3-C6)cycloalkyl, 3-6 membered heterocycloalkyl, aryl(C1-C4)alkyl-, heteroaryl(C1-C4)alkyl-,
aryl(C2-C4)alkenyl-, heteroaryl(C2-C4)alkenyl-, aryl-(C3-C6)cycloalkyl-, heteroaryl- (C3-C6)cycloalkyl-, aryl-(C5-C6)cycloalkenyl-, or heteroaryl-(C5-C6)cycloalkenyl-,
wherein said aryl, heteroaryl, cycloalkyl, or heterocycloalkyl (that is the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group or the aryl, heteroaryl, cycloalkyl, or heterocycloalkyl moiety of the aryl(Ci-C4)alkyl-, heteroaryl(Ci-C4)alkyl-,
aryl(C2-C4)alkenyl-, heteroaryl(C2-C4)alkenyl-, aryl-(C3-C6)cycloalkyl-,
heteroaryl-(C3-C6)cycloalkyl-, aryl-(C5-C6)cycloalkenyl-, or heteroaryl-(C5-C6)cycloalkenyl- group) is optionally substituted by 1-3 substituents each independently selected from the group consisting of halo, hydroxy, cyano, nitro, (Ci-C6)alkyl, halo(CrC6)alkyl,
(Ci-C6)alkoxy, phenoxy-, halo(CrC6)alkoxy, (CrC6)alkylthio-, halo(Ci-C6)alkylthio-, hydroxy(CrC6)alkyl-, amino, (Ci-C6)alkylamino-, ((Ci-C6)alkyl)((Ci-C6)alkyl)amino-, amino-(Ci-C6)alkyl-, (Ci-C6)alkylamino(Ci-C6)alkyl-,
((Ci-C6)alkyl)((Ci-C6)alkyl)amino(Ci-C6)alkyl- -S02NH2, -S02NH(Ci-C6)alkyl,
-S02N((Ci-C6)alkyl)((Ci-C6)alkyl), -CONH2, -CONH(C C6)alkyl,
-CON((Ci-C6)alkyl)((Ci-C6)alkyl), -CO(C C6)alkyl, phenyl, and 5-6 membered
heterocycloalkyl,
and wherein the alkyl, alkenyl, cycloalkyl, or cycloalkenyl moieties of said aryl(CrC4)alkyl- , heteroaryl(Ci-C4)alkyl-, aryl(C2-C4)alkenyl- heteroaryl(C2-C4)alkenyl-, aryl-(C3-C6)cycloalkyl-, heteroaryl-(C3-C6)cycloalkyl-, aryl-(C5-C6)cycloalkenyl- and heteroaryl-(C5-C6)cycloalkenyl- is optionally substituted by 1 -3 substituents each independently selected from the group consisting of halogen, hydroxyl, (CrC4)alkoxy, aryl, (C C4)alkylCO-, ((C C4)alkyl)NHCO-, -CONH2, and oxo;
wherein said optionally substituted aryl is an optionally substituted 6 or 9-10 membered aryl, said optionally substituted heteroaryl is an optionally substituted 5-6 or 9-10 membered heteroaryl group, and said 5-6 membered heterocycloalkyl,
5-6-membered heteroaryl, or 9-10 membered heteroaryl contains 1 -4 hetereoatoms each independently selected from the group consisting of nitrogen, oxygen and sulfur;
R2 is hydrogen, (Ci-C6)alkyl, aryl, aryl(Ci-C4)alkyl-, or 4-6 membered
heterocycloalkyl;
or a salt thereof.
2. The compound or salt according to claim 1 , wherein Ar is an optionally substituted aryl, 5-6 or 9-14 membered heteroaryl group, optionally substituted by 1 -2 substituents each independently selected from the group consisting of halo, hydroxy, cyano, amino, nitro, (CrC6)alkyl, aryl, heteroaryl, halo(CrC6)alkyl, (Ci-C6)alkoxy, halo(CrC6)alkoxy, aryloxy (CrC6)alkylthio-, halo(CrC6)alkylthio-, hydroxy(Ci-C6)alkyl-, amino, (Ci-C6)alkylamino-, ((Ci-C6)alkyl)((Ci-C6)alkyl)amino-, heterocycloalkyl, -S02NH2, -S02N H(CrC6)alkyl, -S02N((Ci-C6)alkyl)((Ci-C6)alkyl), -CO(C C6)alkyl, -CON H2, -CON H(Ci-C6)alkyl, and -CON((C C6)alkyl)((Ci-C6)alkyl).
3. The compound or salt according to claim 1 , wherein Ar is an optionally substituted phenyl, pyridyl, furyl, indolyl, pyrrolyl, imidazolyl, naphthyl, quinolyl, benzimidazolyl, benzothiofuranyl, fluorenyl, acridinyl and carbazolyl.
4. The compound or salt according to claim 1 , wherein Ar is an optionally substituted phenyl optionally substituted by a substituent selected from the group consisting of halo, (CrC6)alkyl, halo(CrC6)alkyl, (CrC6)alkoxy, and halo(Ci-C6)alkoxy.
5. The compound or salt according to claim 1 , wherein Ar is an unsubstituted phenyl.
6. The compound or salt according to any one of claims 1 -5, wherein X is
7. The compound or salt according to any one of claims 1 -6, R is an optionally substituted 6, 9, or 10 membered aryl group, an optionally substituted 5, 6, 9 or 10 membered heteroaryl group, an optionally substituted 6, 9 or 10 membered
aryl(CrC4)alkyl- group, an optionally substituted 5, 6, 9 or 10 membered
heteroaryl(Ci-C4)alkyl- group, an optionally substituted 6, 9 or 10 membered
aryl(C2-C4)alkenyl- group, or an optionally substituted 5, 6, 9 or 10 membered heteroaryl(C2-C4)alkenyl- group,
wherein any of said aryl or heteroaryl, (that is the aryl or heteroaryl group or the aryl or heteroaryl moiety of the aryl(Ci-C4)alkyl-, heteroaryl(Ci-C4)alkyl-,
aryl(C2-C4)alkenyl- or heteroaryl(C2-C4)alkenyl- group) is optionally substituted by 1-2 substituents each independently selected from the group consisting of halo, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, phenoxy-, halo(C1-C4)alkoxy,
hydroxy(C1-C4)alkyl-, amino, (C1-C4)alkylamino-, ((C1-C4)alkyl)((C1-C4)alkyl)amino-, amino-(Ci-C4)alkyl- (C1-C4)alkylamino(C1-C4)alkyl-,
((Ci-C4)alkyl)((Ci-C4)alkyl)amino(Ci-C4)alkyl- -S02N H2, -S02N H(Ci-C4)alkyl,
-S02N((Ci-C4)alkyl)((Ci-C4)alkyl), -CONH2, -CONH(C C4)alkyl,
-CON((Ci-C4)alkyl)((Ci-C4)alkyl), -CO(C C4)alkyl, phenyl, and 5-6 membered heterocycloalkyl,
and wherein the alkyl or alkylene moiety of said aryl(Ci-C4)alkyl-,
heteroaryl(Ci-C4)alkyl-, aryl(C2-C4)alkenyl-, or heteroaryl(C2-C4)alkenyl-, is optionally substituted by 1 -2 substituents each independently selected from the group consisting of halogen, hydroxyl, (CrC4)alkoxy, phenyl, (Ci-C4)alkylCO-, and oxo.
8. The compound or salt according to any one of claims 1 -6, R is an optionally substituted phenyl, naphthyl, imidazolyl, pyridyl, furanyl, thienyl, indenyl, quinolyl, benzimidazolyl, or indolyl.
9. The compound or salt according to claim 8, wherein R is optionally substituted by 1 , 2 or 3 independently selected R1 substituents.
10. The compound or salt according to claim 9, wherein R is a phenyl group, substituted by 0, 1 or 2 independently selected R1 substituents.
1 1 . The compound or salt according to any one of claims 9-10, wherein each R1 substituent is independently selected from the group consisting of fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, nitro, -S02NH2, and phenyl.
12. The compound or salt according to any one of claims 1-6, wherein R is selected from the group consisting of 4-(fluoro)phenyl, 4-(chloro)phenyl, 4-(bromo)phenyl, 4-(iodo)phenyl, 4-(methyl) phenyl, 4-(ethyl)phenyl, 4-(isopropyl)phenyl, 4-(t-butyl)phenyl, 4-(cyano)phenyl, 4-(trifluoromethyl)phenyl, 4-(hydroxy)phenyl, 4-(methoxy)phenyl, 4- (ethoxy)phenyl, 4-(isopropoxy)phenyl, 4-(trifluoromethoxy)phenyl, 4- (difluoromethoxy)phenyl, 4-(phenoxy)phenyl, 4-(methylthio)phenyl, 4-
(trifluoromethylthio)phenyl, 4-(hydroxymethyl)phenyl, 4-(amino)phenyl, 4- (dimethylamino)phenyl, 4-(diethylamino)phenyl, 4-(morpholino)phenyl; 4-(amido)phenyl, 4-(acetamido)phenyl, 4-(acetyl)phenyl, 4-(nitro)phenyl, 4-(sulfonamido)phenyl, and 4- (phenyl)phenyl.
13. The compound or salt according to any one of claims 1-6, wherein R is selected from the group consisting of 3,4-di(methoxy)phenyl, 3,4-di(hydroxy)phenyl, 3,4-di(methyl)phenyl, 3,4-di(fluoro)phenyl, 3-(chloro), 4-(fluoro)phenyl,
2.4- di(chloro)phenyl, 2,4-di(fluoro)phenyl, 2-(hydroxymethyl)phenyl,
3-(hydroxymethyl)phenyl, 3-(cyano)phenyl, 3-(trifluoromethylthio)phenyl, 2-(chloro)phenyl, 2-(trifluoromethyl)phenyl, 2-(hydroxymethyl)phenyl, 3,4,5-tri(methoxy)phenyl,
3,4,5-tri(chloro)phenyl, 2-(fluoro)phenyl, 3-(fluoro)phenyl, 2,6-di(fluoro)phenyl,
2,6-di(methyl)phenyl, 2,6-di(isopropyl)phenyl, 2,6-di(fluoro)phenyl, 2-(fluoro),
4-(bromo)phenyl, 2-(trifluoromethyl), 4-(fluoro)phenyl, 2-(trifluoromethyl), 4-(chloro)phenyl, 2-(methoxy), 4-(trifluoromethyl)phenyl, 2-(chloro), 4-(bromo)phenyl, 2-(fluoro),
4-(bromo)phenyl, 2-(fluoro), 4-(bromo)phenyl, 3,5-di(fluoro)phenyl, and
3.5- di(trifluoromethyl)phenyl.
14. The compound or salt according to any one of claims 1-5 and 7-13, wherein R2 is hydrogen, (d-C6)alkyl or aryl.
15. The compound or salt according to any one of claims 1-5 and 7-13, wherein R2 is H or (C C4)alkyl.
16. The compound or salt according to any one of claims 1-5 and 7-13, wherein R2 is H, methyl or ethyl.
17. The com ound or salt according to claim 1 having Formula (l-a):
wherein n is 0, 1 , or 2, and each R1 is independently selected from the group consisting of fluoro, chloro, bromo, methyl, ethyl, isopropyl, t-butyl, cyano, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy, phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino, dimethylamino, diethylamino, morpholino, -CONH2, -COCH3, nitro, -SO2NH2, and phenyl.
18. The compound or salt according to claim 16 or claim 17, wherein n is 0.
19. The compound according to claim 1 , selected from the group consisting of any one of Examples 1 -2, or a salt thereof.
20. A pharmaceutical composition comprising the compound or salt according to any one of claims 1 -19 and one or more pharmaceutically-acceptable excipients.
21 . A method of inhibiting HDAC comprising contacting a cell with an effective amount of the compound or salt according to any one of claims 1-19.
22. A method of treating an HDAC-mediated disease or condition in a patient comprising administering to said patient a therapeutically-effective amount of the compound or salt according to any one of claims 1-19.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161553295P | 2011-10-31 | 2011-10-31 | |
US61/553,295 | 2011-10-31 | ||
US201261596396P | 2012-02-08 | 2012-02-08 | |
US61/596,396 | 2012-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013066834A1 true WO2013066834A1 (en) | 2013-05-10 |
Family
ID=48192666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/062509 WO2013066834A1 (en) | 2011-10-31 | 2012-10-30 | Compounds and methods |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013066834A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056843B2 (en) | 2011-07-08 | 2015-06-16 | Novartis Ag | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
US11938134B2 (en) | 2017-03-10 | 2024-03-26 | Eikonizo Therapeutics, Inc. | Metalloenzyme inhibitor compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274120A1 (en) * | 2005-11-10 | 2008-11-06 | Topotarget Uk Limited | Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent |
WO2011088187A1 (en) * | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
-
2012
- 2012-10-30 WO PCT/US2012/062509 patent/WO2013066834A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080274120A1 (en) * | 2005-11-10 | 2008-11-06 | Topotarget Uk Limited | Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent |
WO2011088187A1 (en) * | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
Non-Patent Citations (2)
Title |
---|
LAVOIE ET AL.: "Design and Synthesis of a Novel Class of Histone Deacetylase Inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 21, 2001, pages 2847 - 2850, XP002371564 * |
WARMUS ET AL.: "2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, 2008, pages 6171 - 6174, XP025646300 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056843B2 (en) | 2011-07-08 | 2015-06-16 | Novartis Ag | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
US11938134B2 (en) | 2017-03-10 | 2024-03-26 | Eikonizo Therapeutics, Inc. | Metalloenzyme inhibitor compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013066838A1 (en) | Compounds and methods | |
WO2013066835A2 (en) | Compounds and methods | |
WO2013066839A2 (en) | Compounds and methods | |
WO2013066833A1 (en) | Compounds and methods to inhibit histone deacetylase (hdac) enzymes | |
US8901156B2 (en) | Compounds and methods | |
WO2013006408A1 (en) | Compounds and methods | |
US8981084B2 (en) | Oxadiazole HDAC inhibitors | |
WO2013066831A1 (en) | Compounds and methods | |
CN109563057B (en) | Sulfonamide compound or salt thereof | |
US20120322827A1 (en) | Compounds and methods | |
JP5897566B2 (en) | Cyclic N, N'-diarylthiourea and N, N'-diarylurea-androgen receptor antagonists, anticancer agents, methods for their preparation and uses | |
WO2013161919A1 (en) | Trk-INHIBITING COMPOUND | |
JP6846574B2 (en) | Sulfonamide compounds and their use | |
WO2014165090A1 (en) | Compounds for the treatment of tuberculosis | |
CA2738776A1 (en) | 7-azaspiro [3.5] nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase | |
EP4061364A1 (en) | Heteroaryl compounds | |
CN108137608A (en) | 1 selective depressant of JANUS kinases and its medicinal usage | |
WO2013066836A1 (en) | Compounds and methods | |
WO2013066834A1 (en) | Compounds and methods | |
CN110139857A (en) | As the sulphoxide imine of indole amine 2,3-dioxygenase inhibitor, sulfimide amide, sulphonyl diimine and imidodicarbonic diamide sulfonamide compounds | |
WO2013066832A1 (en) | Compounds and methods | |
WO2014159938A1 (en) | Substituted aminothiazoles for the treatment of tuberculosis | |
AU2014246609A1 (en) | Compounds and methods | |
GB2532178A (en) | Antiviral compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12845368 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/08/2014) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12845368 Country of ref document: EP Kind code of ref document: A1 |